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ABSTRACT
Adoption and Impact of Telemental Health on Healthcare Outcomes
in the United States
Xiaohui Zhao
Mental health conditions (MHCs) are the most expensive conditions in the United States
(US). The high MHC prevalence coupled with continued undertreatment of MHC has
contributed significantly to this high economic burden. Despite policy changes to increase
mental health parity and integrate mental and physical healthcare, the shortage of mental health
providers remains a significant barrier to mental health (MH) treatment. Telemental health
(TMH) has emerged as an alternative care delivery approach to meet the growing demand of MH
care and shortages of MH providers. Understanding the adoption of TMH among mental health
facilities is critical for informing the broad implementation of TMH in the delivery system of
mental healthcare. As the use of TMH is determined by not only "supply" but also "demand," it
is also important to understand TMH use among adults with MHC. Given that commercial
insurance plays an important role in paying for mental health services and telehealth services, it
is imperative to examine TMH use and the impact of TMH use on healthcare costs among
commercially insured adults with MHC in real-world care settings. Therefore, this dissertation
pursued three related aims: 1) to estimate TMH adoption and examine factors associated with
TMH adoption among mental health facilities; 2) to characterize TMH use and identify factors
associated with TMH use among commercially insured adults with MHC; and 3) to evaluate how
TMH use influences healthcare costs. To comprehensively present TMH state of the art within
the current mental health delivery system, the study used diverse data sources. These data
sources were: the National Mental Health Services Survey (N-MHSS) for years 2011-2016; a

geographically diverse claims database for commercially insured adults for years 2010-2017; the
latest Area Health Resources File (2016-2017); and national reports of telehealth policies. We
found that about one in four mental health facilities in the US adopted TMH in 2016. TMH
adoption might be hindered by low facility-level information technology capacity and by state
licensure requirements for cross-state telehealth practice. TMH use among adults with MHC was
low (16 in 10,000) in this study of a commercially insured population. Current TMH use among
adults with MHC was driven mainly by a greater need to access mental health specialists. TMH
use was associated with increased MH service use and higher MH-related costs. However, TMH
use did not have a significant impact on total third-party healthcare costs. In summary, these
findings highlight the need for collaborative efforts by policymakers, payers, and providers to
increase the availability of TMH in mental health care delivery, and thereby increase access to
mental healthcare services for adults with MHC. Further research is needed to confirm and
extend our study findings; specifically, studies are needed to examine how TMH use affects the
cost of mental and physical health care separately, and to explore whether TMH use can lead to
cost-savings over a longer period among adults with different MHCs.
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CHAPTER 1
1 Introduction
1.1 Background and Significance
Epidemiology of Mental Health Conditions
Mental health is an indispensable part of an individual's overall well-being, interpersonal
relationships, and ability to contribute to society. Mental health conditions (MHCs) are a wide
range of health conditions characterized by alterations in thinking, mood, and/or behavior that
are associated with impaired functioning.1 The manifestations of MHCs varies by conditions and
individuals, some conditions (e.g., schizophrenia, bipolar disorder, major depressive disorders)
can cause serious functional impairments that substantially interferes daily activities. MHC
affects 44.7 million, or one in five, adults in the United States (US). 2 The resulting disease
burden of MHCs is among the highest across all diseases, accounting for about one-third (32.4%)
of years lived with disability globally.3,4 Furthermore, individuals with MHC die 8 - 32 years
earlier than those without any MHC.5,6
The Burden of Untreated MHCs
Although MHCs can be extraordinary disabling, they can be managed with proper
treatments.7 However, a substantial proportion of adults with MHCs remain untreated. Data from
the 2016 National Survey on Drug Use and Health indicated that 56.9% of adults with MHC did
not receive any treatments in the previous year.2 Untreated MHCs can have a series of
consequences, including worsening the condition and making treatment harder, leading to the
development of chronic physical conditions (e.g., cardiovascular diseases), impairing quality of
life, and increasing suicidal ideation.8 According to the National Alliance on Mental Illness,
untreated mental illnesses cost about $100 billion a year due to productivity loss.9
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Barriers to Mental Health Treatments
Despite policy changes to increase mental health parity and integrate mental and physical
healthcare,10,11 the shortage of mental health providers remains a significant barrier to mental
health (MH) treatments.12,13 As of 2017, there were 5,042 designated Mental Health Care Health
Professional Shortage Areas in the US.14 It is reported that over three-quarters (77%) of US
counties had a severe shortage of mental health providers.15 Insufficient mental health providers
can lead to a long waiting time for patients seeking mental health treatments. A recent study
assessing the access to and attitudes towards mental health services reported that over one-third
(38%) of adults with MHCs had to wait longer than one week for mental health treatments.16
Timely access to mental health services is critical to successful treatment,17 and timelines of care
is a key indicator of quality healthcare.18 Therefore, addressing the shortage of mental health
providers is a critical step in improving mental healthcare in the US.
Other commonly reported barriers included geographical isolation and stigma associated
with visiting mental health providers. 16,19 A study reported that 46% of adults with MHC had to
drive more than an hour to seek mental health services.16 The study also revealed that nearly onethird (31%) of adults with MHC reported worries about being judged when they have sought
mental health services.16
Telehealth and Access to Care
Telehealth is rising as a promising solution to provider shortage and limited access to
care due to geographic barriers.20 Telehealth, often referred to as telemedicine, has many
definitions. Commonly it is defined as “the use of medical information exchanged from one site
to another via electronic communications to improve a patient's clinical health status.” 21 Two
forms of telehealth, namely live interactive video (synchronous telehealth) and store-and-forward
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electronic information exchange (asynchronous telehealth), are currently paid by insurers and
therefore often used in clinical care for consultation, diagnosis, and treatments.22-25 Results from
a systematic review assessing 106 telehealth interventions across various disease areas concluded
that telehealth was most effective for managing care conditions that do not primarily rely on
physical examinations. Thus, telehealth is considered ideal for managing MHCs.26
Telemental health (TMH) and Access to Mental Healthcare
The application of telehealth in mental healthcare is referred as telemental health (TMH),
which includes telepsychology, telepsychiatry, and telebehavioral health.27 Current TMH
applications include mental health assessment, treatment, education, monitoring, and
collaboration among providers. 28 It can be offered by a wide range of providers: primary care
physicians, psychiatrists, psychologists, nurse practitioners, social workers, and counselors.28
TMH has been found effective in removing geographic barriers to mental health treatments by
maximizing the reach of the existing mental health professionals. Furthermore, TMH can expand
the capacity of primary care settings in delivering mental health care by bridging the
communications among mental health professionals, primary care physicians, and patients. A
recent systematic review of 134 studies on TMH concluded that TMH interventions were
effective in improving access to mental health care, especially for those living in isolated areas.29
Given that many adults with MHC do not seek treatment due to the stigma associated with
visiting mental health providers, evidence also suggests that TMH may also increase access by
helping adults with MHCs feel less stigmatized.30-32
Adoption of Telehealth and TMH among Healthcare Providers
The significant advances in information and communication technologies have
accelerated the adoption and use of telehealth in general among healthcare providers and
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facilities. Data from the American Hospital Association annual survey of acute care hospitals
showed that 42% of US hospitals have some forms of telehealth services by 2012.39 The
adoption of telehealth was affected by the type of facility, rurality, population density, and state
policies. Teaching hospitals, those equipped with advanced medical technologies, non-profit
institutions, and those belong to a larger hospital system were more likely to have telehealth
capacities.39 Facilities in rural areas have higher adoption rates than those in urban areas. 39 The
pass of telemedicine parity laws that require private payers to reimburse for telehealth services to
the same extent as in-person services were associated with higher odds of adoption, whereas
state policies that require out-of-state providers to have special licenses when delivering
telehealth services to Medicaid patients reduced the odds of adoption.39
The first step in the wide-spread implementation of TMH in delivering mental health
treatments is the adoption of TMH among mental health facilities. However, little is known
about TMH adoption among mental health facilities. Such knowledge is warranted to inform
policy-making and healthcare resources allocation. This leads to the rationale for Aim 1, which
estimated the adoption rate of TMH and examined state- and facility-level factors associated
with TMH adoption among mental health facilities.
TMH Use among Adults with MHCs
Recognizing the potential for TMH to remove access-related barriers to treatment,
federal, state, and local governments have made substantial efforts to increase TMH services in
recent years.40 However, only a few studies have examined TMH use among adults with MHCs
in real-world settings using recent data. One study analyzing 2008 and 2009 Medicaid claims
reported very low (< 0.1%) TMH use and high state-level variations due to differences in
coverage and reimbursement policies for TMH across states.41 Notable variations in TMH use
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were also reported in a study analyzing 2004-2014 claims data of Medicare beneficiaries with
MHCs, who had the same TMH coverage and reimbursement policies.42 While these studies
illustrated the role of reimbursement policies in TMH use, they also highlighted the wide
variation in TMH use among states, despite having the same reimbursement and coverage for
TMH services. This finding suggests that patient characteristics and state-level factors may also
contribute to TMH use. Previous studies have reported that TMH use was significantly
associated with younger age, having any disability, and living in a poor community.43,44 Health
plan characteristics (e.g., out-of-pocket expenditures 45), factors that may increase the need for
TMH/MH services (e.g., previous treatment seeking,46 polypharmacy 47), and environmental
capacities that allow TMH use were not explored.
Adoption of Telehealth and TMH among Healthcare Payers
Like any other healthcare services, telehealth adoption by healthcare payers is essential to
the overall deployment of telehealth. The overall reimbursement environment for telehealth
services is improving over time in both public and private sectors, with large variation by
payers.33 The Veterans Health Administration (VHA) is the largest payer of telehealth services,
including TMH, in the US. The VHA telehealth programs encompass 44 clinical specialties in
various clinical settings (e.g., emergency care, intense care unit).34 Unlike the VHA, the
Medicare fee-for-service (FFS) programs limit reimbursement and coverage for telehealth by
types of healthcare professionals, modalities of telehealth services, geographic locations where
patients receive care (i.e., originating site).35,36 For example, Medicare FFS programs cover only
cover synchronous TMH services for beneficiaries living in rural areas or areas with shortages of
providers.35,36 Medicare Advantage (MA) plans may cover telehealth services and/or areas
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beyond the FFS programs’ coverage after the approval of the Centers for Medicare and Medicaid
Services.35,36
Telehealth reimbursement policies vary widely in Medicaid programs and private
insurances. As for 2017, all 50 state Medicaid programs have some type of coverage for TMH.37
Private insurers have embraced telehealth better than public insurers,38 with all top-ten health
insurance companies have covered TMH in their plans. There is evidence showing that private
payers are more likely to be billed for telehealth services than public payers.38
While private insurance provides an important source of health coverage for adults with
MHCs,48 knowledge about TMH use among commercially insured adults with MHC is limited.
Although TMH has been covered for almost all MH services from various providers (e.g.,
psychiatrists, social worker, physicians),49 how TMH is used in various MH services and who is
delivering TMH in real-world practice remained unknown. Such knowledge is vital to inform
health insurers and healthcare policymakers how to better incorporate TMH in delivering mental
health services into real-world healthcare settings. These knowledge gaps lead to the rationale
for Aim 2, which estimated TMH use, explored the role of TMH use in delivering MH services,
and examined the associations of patient- and state-level factors to TMH use among adults with
MHCs using linked claims data from a large U.S. commercial plan.
The Comparative Efficacy of TMH versus In-person Services
Results of randomized clinical trials and systematic reviews have demonstrated that TMH
in various modalities (e.g., internet, phone, video-conferencing) is comparable or even superior
to in-person care in assessing and treating adults with MHCs across different diagnostic and
demographic groups. 50-54 The majority of TMH studies have focused on anxiety and mood
disorders, probably due to their high prevalence and their amenability to remote treatments.54
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Specifically, there is consistent evidence revealing that TMH is associated with higher treatment
adherence and improved depressive symptoms as compared to in-person care.55-57 Studies
evaluating TMH in assessing and treating serious MHCs such as schizophrenia and bipolar
disorders are also rising.58,59 Preliminary evidence suggested that TMH appeared to improve
outcomes of serious MHCs. 58,59
The Impact of TMH use on Healthcare Outcomes in Real-world Care Settings
Although the comparative efficacy of TMH in delivering MH care as compared to inperson care is well-documented in clinical trials, real-world evidence on healthcare outcomes
associated with TMH use among adults with MHCs was lacking. Existing evidence primarily
comes from studies using data from the VHA. A study examining outcomes of 98,609 veterans
receiving TMH services reported a 25% reduction in psychiatric admissions and hospital stays
after initiating TMH over four years. 60 However, the study did not have individuals receiving
only in-person MH services as controls. 60 Studies comparing outcomes among MHC patients
receiving TMH and in-person MH services are warranted to establish the value of TMH services.
Given the limited healthcare resources, healthcare costs have always been an essential
measurement of healthcare outcomes in the US. In response to the rising healthcare costs, the
Institute of Health Improvement developed the “Triple Aim” to define high-value care as those
can improve population health and individual care experience with reduced per-capita costs.61 To
be aligned with the “Triple Aim,” the National Quality Forum (NQF) and the American
Telemedicine Association (ATA) used healthcare costs as one of the key measurements in their
newly developed telehealth value framework.62
Existing studies have primarily focused on indirect medical costs such as time and
expenses related to travel. TMH has been found effective in reducing the costs of traveling
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among patients as well as providers.63-66 No study has compared direct healthcare costs between
MHC patients who used TMH services and those used only in-person MH services. Such
knowledge can provide valuable insights to healthcare payers regarding the expansion of TMH
coverage.67 This leads to the rationale of aim 3, which examined the association of TMH use with
direct healthcare cost among adults with MHC by comparing the total and MH-related costs
among adults with MHC who used TMH services and those used in-person MH service only from
a commercial insurance’s perspective.
1.2 Innovation
a) Comprehensive analysis of the factors associated with TMH adoption among mental
health facilities: This is the first study to estimate the TMH adoption rate and examine
state- and patient-level factors associated with TMH adoption among mental health
facilities in the US with a linked population-based data.
b) Examination of the association between state-level TMH capacity and TMH use
among commercially insured adults with MHCs in the US: This is the first study to
examine the association between the state-level adoption of TMH among mental health
facilities and TMH use among adults with MHCs who were enrolled in a geographically
diverse commercial health insurance in the US.
c) Description of the role of TMH in delivering mental health services: the first study to
characterize the role of TMH in delivering various mental health services among adults
MHCs enrolled in a large commercial health insurance in the US.
d) Application of econometric techniques to evaluate the impact of TMH use on total
third-party healthcare costs and MH-related costs: This is the first study to evaluate
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how TMH use influences total healthcare costs MH-related costs from a third-party
payer’s perspective.
e) Use of a geographically diverse data of commercially insured adults with MHCs:
Data from the Optum Clinformatics ® DataMart allows the examination of TMH use
among commercially insured adults with MHCs across all 50 states and the District of
Columbia.
f) Use of standard prices of healthcare services and prescription drugs to measure
third-party healthcare costs: The standard prices provided by Optum Clinformatics ®
DataMart estimated the allowed payments from insurers with standard pricing algorithms
that account for types of services, the quantity of services, and relevant resources cost
involved in providing the services. In this way, the healthcare costs of commercially
insured adults with MHCs from different geographic areas and those enrolled in different
insurance plans can be compared in a consistent manner.
1.3 Specific Aims
AIM 1: Estimate TMH adoption rates and examine state- and facility-level characteristics
associated with TMH adoption among mental health facilities.
Hypothesis: TMH adoption will be more likely in facilities with non-profit ownership,
higher IT capability, more elderly patients, and those located in states with friendly
telehealth policies and higher levels of provider shortage.
AIM 2: Characterize TMH use and identify state- and patient-level factors associated with
TMH use among commercially insured adults (age > 18 years) with MHCs.
Hypothesis: TMH will be more likely to be used by MHC patients who are younger,
enrolled in managed care plans, and those with severe MHCs; Patients residing in states
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that have a higher percentage of rural counties or higher provider shortage will be more
likely to use TMH as compared to those residing in states that are less rural and with a
lower provider shortage.
AIM3: Evaluate the impact of TMH use on total third-party healthcare costs and MHrelated costs among commercially insured adults (age > 18 years) with MHCs.
Hypothesis: TMH use will increase MH-related healthcare costs but will not influence total
third-party healthcare costs.
1.4 Approach
Conceptual Framework
Aim 1: The conceptual framework for Aim 1 was built on common constructs and factors
that have been examined in previous studies on telehealth, electronic medical record (HER), and
other health information technologies (HITs).68-70 The model posits that the adoption of TMH by
a healthcare facility is a result of multilevel factors, including environmental resources, policy-,
market-, and facility-level characteristics. The environmental resource most pertinent to TMH
use is the local broadband access (25 Mbps/3 Mbps service).71 Policy characteristics include 1)
state-level coverage and reimbursement policies for TH; 2) licensure policies that require
providers to have licenses for cross-state TH practice, and 3) state consent policies that require
some informed consent by patients before receiving TH services. Market characteristics consist
of factors that influence the demand for TMH. Such factors include the level of rurality and the
shortage of health care providers (i.e., primary care and mental health). Facility characteristics
that may affect TMH adoption can be grouped into five domains: 1) facility type (e.g., care
setting, ownership, affiliation, and volume of patients); 2) comprehensiveness of mental health
treatment (e.g., treatment focus, the number of mental health treatment approaches, services, and
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special programs, the availability of non-English services); 3) quality improvement practice 4)
Information Technology capacity; and 5) payer-mix (e.g., Medicare, Medicaid, Veteran Health
Administration) and case-mix, which includes the demographic composition (e.g., age, sex,
race/ethnicity) and percentages of high-need patients (e.g., veterans, patients with co-occurring
mental health and substance abuse).
Aim 2: The conceptual framework of Aim 2 was adapted from the determinants of health
model proposed by Wilkinson and Marmot,72 and the Telehealth Research and Policy
Framework proposed by a multidisciplinary group of experts and literature review.73 The model
suggests that factors that affect TMH use can be grouped into four domains, including 1)
biological factors (e.g. age, sex); 2) health insurance characteristics (e.g., Medicare Advantage
Enrollment, type of health plan, out-of-pocket expenditures); 3) need factors (e.g., severity of
MHC, any mental health specialist visit, physical chronic conditions, polypharmacy, substance
use disorders, obesity); as well as 4) environmental factors (e.g. poverty, rurality, healthcare
provider shortage, TMH capacity).
Aim 3: The conceptual framework of Aim 3 was based on the adapted Andersen’s
Behavioral Model of Health Services Use,74 which posits that healthcare utilization of an
individual is a function of multiple factors. These factors can be grouped into four domains,
including 1) predisposing factors that represent the individual characteristics predictive of using
healthcare services (e.g., age, sex); 2) enabling factors that may enable access to healthcare
services (e.g., TMH use, type of health insurance, type of insurance plan); 3) need factors that
define an individual’s health status (e.g., severe MHC diagnosis, mental health specialist visits,
the number of physical chronic conditions, the presence of polypharmacy, obesity, and any
substance use disorders); and 4) environmental factors that may influence an individual’s
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healthcare utilization (e.g., % counties under poverty, % rural counties, % counties with MH
provider shortage, and % MH facilities with TMH adoption).
Data Sources
To accomplish the study objectives, we used data from multiple sources. To estimate the
TMH adoption and examine state- and facility-level factors associated with TMH adoption
among mental health facilities (Aim 1), we used linked data from five sources: 1) 2016 National
Mental Health Services Survey (N-MHSS); 2) the 2016-2017 Area Health Resources File
(AHRF); 3) the 2016 Broadband Progress Report from the Federal Communications
Commission; 75 4) the State Telemedicine Gaps Analysis: Coverage & Reimbursement from the
ATA; 76 and 5) the State Telehealth Laws and Reimbursement Policies from the Center for
Connected Health Policy (CCHP).77 The N-MHSS is an annual survey conducted by the
Substance Abuse and Mental Health Services Administration of all known public and private
mental health treatment facilities throughout all 50 states, the District of Columbia, and other US
jurisdictions. It is the only source of national and state-level data on the mental health services
delivery system for publicly- and privately-operated specialty mental health care facilities.78 NMHSS collects a comprehensive set of information on facility type, primary treatment focus,
mental treatment characteristics, management characteristics such as computerized functionality,
payer mix, licensing, certification, or accreditation, as well as demographics of patients.78 The
AHRF include data on healthcare providers, population characteristics and environment at the
county, state and national levels from over 50 data sources.
To characterize TMH use, identify state- and patient-level factors associated with TMH
use (Aim 2), and evaluate the impact of TMH use on healthcare costs (Aim 3), we used linked
data from several sources: 1) de-identified 10% sample of the Optum Clinformatics ® DataMart
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(Optum Clinformatics ®, Eden Prairie, MN, USA) from 1st January 2010 through 30th June 2017;
2) 2016-2017 AHRF; and 3) the 2010 – 2016 N-MHSS. Optum Clinformatics ® provides
deidentified paid medical and prescription claims for individuals enrolled in the commercial
insurance plans and Medicare Advantage plan of a large U.S. health insurance company. This
databases also encompass demographic characteristics (i.e., year of birth, gender, residential
state) and plan type (e.g., health maintenance organization, preferred provider organization, point
of service, fee-for-service) that are routinely collected during health insurance enrollment.79

13

CHAPTER 2
2 Facility and State-level Factors Associated with Telemental Health (TMH) Adoption
Among Mental Health Facilities in The United States (US)
2.1 Abstract
Introduction: Telemental health (TMH) is a promising approach to increase access to mental
healthcare. This study examined the TMH adoption rates and associations with facility and statelevel factors among US mental health (MH) facilities. Methods: This retrospective, crosssectional study used linked data for 2016 from the National Mental Health Services Survey (N =
11,833), Area Health Resources File, and national reports for broadband access and telehealth
policies. The associations of facility and state-level characteristics with TMH adoption were
examined with multi-level logistic regressions. Results: Overall, 25.9% had adopted TMH.
Having veteran affiliation [Adjusted Odds Ratio (AOR) = 18.53, 95% Confidence Interval
(95%CI): 10.66–32.21] and high Information Technology (IT) capacities [AOR (95%CI):
2.89(2.10–3.98)] were the strongest correlates of TMH adoption. Other facility characteristics
indicating higher TMH adoption were: having public ownership, high patient volumes,
comprehensive MH treatments or Quality Improvement practices, private or non-Medicaid
public payers, and treating elderly patients (AORs: 1.16 – 2.41). The adoption was less likely
among facilities treating more patients with substance abuse disorders or African Americans.
TMH adoption varied substantially across states, with adoption more likely in states issuing
special telehealth licenses and those with more rural counties. Discussion: One in four MH
facilities adopted TMH in 2016. TMH adoption varied by multiple facility- and state-level
factors. Our findings suggest that: legal/regulatory burden and lower facility IT capacity may
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discourage TMH adoption; significant racial disparities exist in TMH access, and there is a need
to increase TMH use for substance use disorders.
2.2 Introduction
Mental health conditions (MHCs) affect 44.7 million adults in the US;2 one in five adults
experience an MHC in a given year.2 Although MHCs can be highly disabling, they can be
managed with proper treatments.7 Despite policy changes to increase mental health parity and
integrate mental and physical healthcare,10,11 50% of adults with MHCs remain untreated.2
Untreated MHCs can impose a heavy burden on individuals, their families, payers, and society.
8,80

The shortage of mental health providers remains a significant barrier to mental health (MH)

treatments.12,13 As of 2017, there were 5,042 designated Mental Health Care Health Professional
Shortage Areas in the US.14
Tele-mental health (TMH), the delivery of MH services through remote technologies
(e.g., video-based conferencing), is emerging as a promising solution to the shortage of
providers.27 Existing studies have demonstrated the efficacy of TMH in removing geographic
barriers to MH treatments 60,81 and facilitating the collaboration between primary care providers
and mental health providers.82 Given that many patients do not seek MH treatment due to the
stigma associated with in-person visits to mental health facilities, TMH may also increase
treatment seeking by “bringing” mental health providers to primary care settings.30-32
Furthermore, a recent review of eight systematic reviews of TMH interventions indicated that
TMH was comparable to in-person care in assessing and treating various mental health
conditions.83 As TMH has great potential for improving mental healthcare delivery, it is
important to understand how TMH is implemented in real-world healthcare settings.
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The first step in the wide-spread implementation of TMH is the adoption of TMH in
mental health facilities. Adoption of TMH may be determined by multiple factors. However,
rigorous studies of TMH adoption rates are lacking. Likewise, although several studies have
investigated factors associated with the adoption of Electronic Medical Record (EMR) system
and other Health Information Technologies (HITs), 39,68-70 little is known about the factors
associated with TMH adoption. Such knowledge is needed to inform healthcare policy and
allocation of healthcare resources as well as to improve healthcare outcomes of patients with
mental health conditions through TMH-affiliated collaborative care. Therefore, this study aimed
to (1) estimate the TMH adoption rate and (2) examine facility and state-level factors associated
with TMH adoption among mental health facilities in the US using linked population-based data.
2.3 Methods
Study design and data sources
This retrospective cross-sectional study used linked data from five sources: 1) 2016
National Mental Health Services Survey (N-MHSS); 2) the 2016-2017 Area Health Resources
File (AHRF); 3) the 2016 Broadband Progress Report from the Federal Communications
Commission; 75 4) the State Telemedicine Gaps Analysis: Coverage & Reimbursement from the
American Telemedicine Association (ATA); 76 and 5) the State Telehealth Laws and
Reimbursement Policies from the Center for Connected Health Policy (CCHP).77 The N-MHSS
is an annual survey conducted by the Substance Abuse and Mental Health Services
Administration (SAMHSA) of all known public and private mental health treatment facilities
throughout all 50 states, the District of Columbia, and other US jurisdictions. It is the only source
of national and state-level data on the mental health services delivery system for publicly and
privately operated mental health care specialty facilities. 78 N-MHSS collects a comprehensive
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set of information on facility type, primary treatment focus, mental treatment characteristics,
management characteristics such as computerized functionality, payer mix, licensing,
certification, or accreditation, as well as demographics of patients. 78 The survey universe was
identified from the database produced after fielding the 2010 and 2014 N-MHSS. 78 The 2016 NMHSS was conducted from March 2016 through January 2017 among 13,983 facilities across
the nation with a response rate of 91%. A total of 12,172 facilities were eligible for reporting in
the final dataset.78
The Area Health Resources File (AHRF) for 2016 was used to identify state-level
population characteristics and healthcare resources. The AHRF data provide county, state and
national-level data on health care professions, health facilities, population characteristics, and the
general environment from over 50 valid data sources, including the American Medical
Association, the American Community Survey, and the U.S. Census Bureau. 84
Study population
The study population included 11,883 mental health facilities located in the 50 states and
the District of Columbia that responded to the query about TMH use and patient characteristics
in the 2016 N-MHSS. Facilities in American Samoa, Guam, Puerto Rico, and the Virgin Islands
were excluded due to insufficient information on telehealth policies (N = 99).
Measures
Dependent Variable: TMH adoption (Yes/No)
The dependent variable was TMH adoption of mental health facilities. A binary variable
(yes/no) was created based on the responses of the N-MHSS question “which of these mental
health treatment approaches are offered at this facility, at this location?” from the facility
director. The survey provided a checklist of items and facilities that checked the item of
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“telemedicine therapy” were identified as facilities with TMH adoption, whereas those that did
not check this item were identified as facilities without TMH adoption.
Explanatory Variables:
The explanatory variables were selected based on the common constructs and factors that
have been examined in previous studies on telehealth, EMR, and other HITs.39,68-70 Consistent
with the findings of these studies, we hypothesized that the adoption of TMH by a mental health
facility may be associated with multiple state-and facility-level factors, including environmental
resources, policy, market, and facility-level characteristics.
Facility-level characteristics were measured in five domains: 1) facility type that included
care setting, ownership, affiliation, and volume of patients; 2) comprehensiveness of mental
health treatment, including treatment focus, the number of mental health treatment approaches,
services, and special programs as well as the availability of non-English services; 3) quality
improvement (QI) practice; 4) Information Technology (IT) capacity; and 5) payer mix
[Medicare/Medicaid/Veteran Health Administration (VHA)] and case-mix, which included
demographic composition (e.g., age, sex, race/ethnicity) and percentages of high-need patients
[e.g., % veteran patients and % patients with co-occurring mental health and substance abuse
(MHSA)]. The IT capacity was defined as the level of technology involvement in 14 routine
facility activities. The level of technology involvement was measured by the mean score of all
activities rated on a 3-point scale, where “1” denotes no technology involvement (i.e., rely on
paper), “2” indicates partial involvement (i.e., both electronic and paper), and “3” represents
fully involvement (i.e., only electronic).
State-level characteristics included environmental resources, telehealth policy, and
market characteristics. Environmental resources were measured as the percentage of counties
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with broadband access (25Mbps/3 Mbps service) based on the 2016 Broadband Progress
Report.75 The telehealth policy environment was measured by three factors: 1) reimbursement
and coverage of telehealth; 2) licensure policies that require providers to have special licenses for
cross-state telehealth practice, and 3) consent policies that require informed consent by patients
before receiving any telehealth services. We used the ATA grading (A/B/C/F) to represent the
overall reimbursement and coverage environment of each state. 76 The summary grades were
developed based on 13 indicators that included telehealth parity, Medicaid policies, and
innovative payment models.76 The licensure and consent policy for each state were obtained
from CCHP’s State Telehealth Laws and Reimbursement Policies Report.77 We categorized the
licensure policy of a state into five groups: 1) requiring individual state license, 2) adopting the
Federation of State Medical Boards (FSMB)’s Interstate Medical Licensure Compact policy that
allows for an expedited application for licenses in participating states; 3) issuing special
telehealth license, 4) having exemptions for acceptable practice or states, and 5) not requiring
licenses or policy not defined. The consent requirement of a state was dichotomized as “yes (i.e.,
consent needed)” and “no (i.e., consent not needed).” Market characteristics were derived from
the 2016-2017 AHRF and included factors that influence the demand for TMH: the level of
rurality represented by the percentage of rural counties (2013 rural-urban continuum code of 8
and 9) and provider shortages for primary care providers (PCP) and mental health providers
(MHP). 84 We categorized provider shortage into three groups based on percentages counties that
were designated as shortage areas in the state: 1) high (states ranked on 4th quartile for both PCPs
and MHPs were considered having high level of shortage); 2) moderate (states ranked on 2nd or
3rd quartiles for either PCPs or MHPs) and 3) low (states ranked on 1st quartile for PCPs and
MHPs).
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Statistical analysis
TMH adoption rates were calculated for all mental health facilities and for specific
subgroups of MH facilities categorized by facility and state-level characteristics (environmental
resource, policy and, market characteristics). The adjusted association of each explanatory
variable and TMH adoption was examined with multi-level logistic regressions because facilities
(Level-1) were nested within states (Level-2). The level-1 variables included all the facility
characteristics, and the level-2 variables included the state-level environmental resource,
telehealth policy environment, and market characteristics. Wald chi-square tests were used to
evaluate state variance in TMH adoption. Variance Partition Coefficients (VPCs) were calculated
to quantify variance due to differences between states. Several 2-level logistic regressions were
constructed to identify significant factors associated with TMH adoption. The model-building
process is outlined in Table 1. Model 1 was an unconditional model where only the intercept was
fitted. Model 2 was a random intercept model where all the level-1 explanatory variables were
fitted, whereas Models 3 - 5 had level-2 variables added stepwise. The likelihood-ratio (LR) test
was used to assess the significance of 2-level models versus (vs.) 1-level models. Data
management and analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC) and
Stata 14 (StataCorp LLC, College Station, TX).
2.4 Results
Description of mental health facilities
As illustrated in Table 1, most facilities were outpatient settings (84.8%), were private
non-profit (64.0%), did not have religious affiliations (93.3%), and had high patient volume
(54.6%, >100 patients daily). Most focused on mental health only (67.5%), offered
comprehensive mental health treatments (56.1%-83.4%), implemented four or more QI practices
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(71.2%), or had moderate to high IT capabilities (78.9%). Most facilities had Medicaid (88.5%),
Medicare (68.3%), private insurances (80.0%) in their payer-mix. The patient mix in most
facilities included at least some elderly (64.9%) and racial/ethnic minority (i.e., African
American, Hispanic/Latino, Asian, American Indian, Pacific Islanders) patients (95.2%); highneed patients such as veterans and patients with MHSA comprised less than 50% in most
facilities (54.3%-77.5%). On the state level, most facilities were in states that had grade A/B
telehealth reimbursement and coverage (82.4%), needed patient consent for telehealth services
(68.4%), and required some forms of licenses for cross-state telehealth practice (62.4%). More
than one-third of facilities were in states with a high shortage of PCPs and MHPs; almost twofifths were in states with high percentages (i.e., > 20%) of rural counties. About half of the
facilities were in states with poor broadband access.
Description of TMH adoption among mental health facilities
Overall, 25.9% of mental health facilities reported adopting TMH as one of their
treatment approaches. The adoption of TMH varied widely by facility-level characteristics,
ranging from 10.7% in residential facilities to 92.6% in Veteran Administration Health Centers
(VAHCs) (Table 2). TMH adoption rates were highest in Veteran facilities (87.7%), facilities
with higher treatment capacities (28.7%-83.1%), and those with high IT capacities (55.0%). At
the state level, the adoption rates varied from as low as 3.4% in Connecticut to as high as 68.8%
in North Dakota. Adoption rates varied by environmental resource, policy and market
characteristics. Adoption rates (42.1%) were the highest in states with high broadband access,
and the lowest (16.1%) in states with low levels of provider shortages (Table 2).
Facility-level factors associated with TMH adoption
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Results from the fully adjusted analyses (Model 5) indicated that facility characteristics in
all five domains (facility type, comprehensiveness of mental health treatment, QI practice, IT
capability, and payer and case-mix) were significantly associated with TMH adoption (Table 3).
It is noteworthy that Veteran Administration Health Centers were 18 times more likely to adopt
TMH as psychiatric inpatient facilities [Adjusted Odds Ratio (AOR) = 18.53, 95% Confidence
Interval (95%CI): 10.66–32.21]. Facilities with high IT capacities were almost three times more
likely as those with low capacities to have TMH (AOR = 2.89, 95%CI: 2.10–3.98). Other facility
characteristics associated with higher likelihood of TMH adoption included: inclusion of
outpatient settings; high patient volume; public ownership; availability of comprehensive MH
treatment; use of QI practices; private or non-Medicaid public payers; and treating elderly
patients or higher percentages of veterans (AORs: 1.16 – 2.41). On the other hand, facilities that
were affiliated with religious organizations [AOR (95%CI): 0.72 (0.57-0.91)] or treated higher
percentages of African American patients [AOR (95%CI): 0.74 (0.65-0.85)] or patients with
MHSA (AORs: 0.81- 0.83) were significantly less likely to have adopted TMH (Table 3).
State-level factors associated with TMH adoption
As presented in Table 1, results of Wald Chi-square tests indicated significant variation in
TMH adoption across states. Adding environmental, policy, and market characteristics (level-2
variables) into the model (Model 5) reduced the proportion of variance in TMH adoption due to
state variance from 15.9% to 6.5% (Table 1). Market characteristics contributed most to the
variance reduction (14.1% in Model 3 to 7.0% in Model 4). In the fully adjusted model (Table
3), licensure policy and rurality were significantly associated with TMH adoption. Facilities
located in states having a special application process for licenses used in cross-state telehealth
practice were more than twice as likely to have adopted TMH as compared to those located in
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states not requiring or defining such license [AOR = 2.24, 95% Confidence Interval (95%CI):
1.16 – 4.32]. The odds of TMH adoption across states increased with increasing percentage of
rural counties (AORs: 2.09-2.36, p < 0.01). Other policy factors, provider shortages, and
broadband access were not associated with TMH adoption.
2.5 Discussion
In this large population-based study of U.S. mental health facilities, only 26% reported
using TMH as a treatment approach in 2016. This adoption rate was much lower than the rate
reported for general telehealth (42%) in acute care hospitals (American Hospital Association
Annual Survey of Hospitals), 39 but consistent with findings from the American Medical
Association’s 2016 Physician Practice Benchmark Survey indicating that 27.8% of psychiatrists
had used telemedicine to interact with patients.85 One reason for the discrepancy in adoption
rates may be the high need in acute care hospitals for telehealth services such as teleradiology,
teledermatology, teleophthalmology, and telecardiology.86,87
Our results indicated that the adoption of TMH by a mental health facility could be
influenced by multiple factors, including the type of facility, MH treatment capacities, IT
capability, QI practice, and payer and case-mix of the facility. For example, TMH adoption was
significantly higher in Veteran Administration Medical Centers and facilities that had higher
proportions of veteran patients. As the nation's largest health care system, the VA has been the
leader in telehealth in the US since 2003.88 In addition to the VA's continuous commitment to
telehealth and mental health, the integrated nature of the system may also contribute to the
adoption of TMH.39,89 Mental health facilities that included outpatient settings were also more
likely to have TMH, likely reflecting the fact that most MH services adapted to TMH are
provided in outpatient settings. 28,52 Consistent with previous reports,39,69,70 ownership was also
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strongly associated with TMH adoption. In addition, public mental facilities were more likely to
adopt TMH as compared to private for-profit facilities, perhaps due to differences in fiscal
incentives.90,91 Given that most mental health facilities were private non-profit, future studies
should explore barriers to TMH adoption among non-profit facilities to invest in TMH.
In addition to facility type, higher IT capacity was associated with higher TMH adoption.
This association may in part reflect differences in infrastructure. For example, facilities with
higher IT capacities are likely those with a patient referral, health records, and/or provider
collaboration system (i.e., part of the definition of IT capacity in our study). These systems are
often required for effective and sustainable TMH implementation.92 TMH adoption was also
more likely among facilities with comprehensive MH treatments. It is plausible that facilities that
adopted TMH can get access to remote specialists, thereby offering a variety of MH services. As
this was a cross-sectional study, we are unable to parse out whether TMH led to comprehensive
services.
Facility payer type and patient-mix were also significantly associated with TMH
adoption. Facilities treating patients insured by Medicare, VHA, and private payers were more
likely to adopt TMH. Facilities treating elderly patients were more likely to have TMH as
compared to those who did not. The often complex health care needs of elderly patients with
mental health conditions may contribute to TMH adoption, as TMH may facilitate the integrated
management of mental and physical chronic conditions.93 In contrast, TMH adoption was
significantly less likely among facilities serving higher percentages of African Americans,
possibly due to lack of trust in new health care innovations among this group.94 George and
colleague reported that African Americans showed more concerns about confidentiality, privacy,
and care quality of telemedicine as compared to Hispanic controls.95 As African Americans tend
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to experience more severe mental health conditions due to access barriers,96 demonstration and
educational programs are needed to increase the “buy-in” of TMH among African American
patients.
Facilities that primarily served patients with co-occurring mental health and substance
abuse disorders were significantly less likely to adopt TMH relative to those serving fewer
MHSA patients. TMH has been considered a promising tool to combat the U.S. substance abuse
crisis by improving access to substance abuse experts and mental health specialists. 97 However,
TMH benefits may be limited due to the legal restriction on prescribing Medication-Assisted
Treatments via TMH.98 Policy initiatives such as the Improving Access to Remote Behavioral
Health Treatment Act of 2018, which aims to boost availability of Medication-Assisted
Treatment prescribers and ease legal restrictions, may help fully realize the potential of TMH in
behavioral health.98
TMH adoption rates varied substantially across states, and the variation was primarily
driven by differences in telehealth policies and level of rurality. TMH adoption was more likely
in states with more rural counties. This finding is consistent with the previous report on
telehealth adoption among acute hospitals. The higher telehealth/TMH adoption in rural areas
might be a result of financial incentives provided by federal and foundation funding that focuses
on rural health.39,99,100 Mental health facilities located in states that had a special application
process for licensure for providing interstate telehealth services were more likely to have TMH,
than those in states without specific licensure requirements. As of 2017, medical boards in nine
states had established processes to issue telehealth-specific licenses to allow out-of-state
providers to provide telehealth services.77 Twenty-two states had adopted the Federation of State
Medical Board’s Interstate Medical Licensure Compact to allow an expedited process of
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applying for licenses in other states.77 Although adopting the Compact policy was not associated
with TMH adoption in our results, it could nonetheless help increase future TMH adoption, as
more states adopt this policy and facilities acclimatize themselves to this new policy. In contrast
to the observed associations of TMH adoption to state licensure policies, telehealth
reimbursement and consent policy were unrelated to TMH adoption, likely reflecting the
improvement in overall telehealth coverage and reimbursement in recent years. 76
This is the first study to our knowledge to investigate TMH adoption rates and associated
multilevel factors among U.S. mental health facilities. Additional strengths include the large,
representative sample and the use of comprehensive linked data from all 50 states and the
District of Columbia. Our findings not only provide robust estimates of overall TMH adoption
rates in U.S. mental health facilities but also offer insight into factors that may influence facilitylevel decisions to invest in TMH and suggest potential strategies to increase adoption. However,
several limitations should be noted. First, we estimated TMH adoption based on the reported
telemedicine use among mental health facilities, and our data did not allow determination of how
telemedicine was used. Thus, we may have over-estimated TMH adoption and use. Second,
limited data availability only allowed us to measure environmental resources and market
characteristics at the state level; thus we were unable to capture within-state variation in these
factors. In addition, we were not able to capture the financial profile of mental health facilities or
potential market competition, which could also affect the decision to invest in TMH.
Furthermore, N-MHSS did not adjust for non-response; the results of our study may not be
generalizable to facilities (9.9%) that did not participate in the 2016 N-MHSS. Finally, as the
study relied on cross-sectional data, relationships should be considered associative rather than
causal.
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In summary, although TMH appears to offer a promising tool for facilities to expand
access to care and serve high-need patients, only one in four mental health facilities adopted
TMH in 2016. TMH adoption was affected by multiple facility and state-level factors. The legal
or regulatory burden on providers in seeking licensure for cross-state practice and low facility IT
capacity may discourage TMH adoption. Racial disparities in TMH access warrant further
attention. Policy initiatives that could facilitate the prescribing of substance use disorder
medications via TMH are needed to increase access to care for patients with substance use
disorders.
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Table 2.1 Model building process for multi-level multivariable logistic regressions on Telemental
health (TMH) adoption among mental health facilities in the United States.
Model 1

Model 2

Model 3

Model 4

Model 5

Model description

Unconditional
random
intercept
model with
state

level-1
variables a

level-1
variables a &
level-2
variables
(policy)

level-1
variables a &
level-2
variables
(policy &
market) b

Level-2 residual variance
(Standard error)
Wald Chi-square d

0.584 (0.129)

0.624 (0.141)

0.541 (0.124)

0.249 (0.062)

level-1
variables a &
level-2
variables
(policy &
market &
environmental
resource) b
0.230 (0.059)

4.527 *

4.425 *

4.363 *

4.016 *

3.905 *

0.151

0.159

0.141

0.070

0.065

VPC e
Model fit (-2LL)

f

898.73

***

714.00

***

542.39

***

266.24

***

233.00 ***

Note: The study population included mental health facilities located in the 50 states and the District of Columbia that
responded to the query about telemedicine use and patient characteristics in the 2016 N-MHSS. Facilities in American Samoa,
Guam, Puerto Rico, and Virgin Islands were excluded due to insufficient information on telehealth policies.
a level-1 variables included all facility characteristics: the type of facility setting, ownership, religious affiliation; the number
of mental health treatment approaches, mental health services, mental health programs, as well as quality improvement
practice, the availability of non-English service, the IT capacity, the acceptance of Medicare, Medicaid, or Veteran Health
Administration patient, licensing, certification, or accreditation of the facility, average daily number of patients, the number of
mental health admissions in last year, the percentage of veteran patients in last year, and daily patient composition [e.g., % cooccurring mental health and substance abuse patients, % female, % elderly (> 65 years old), % Hispanic/Latino, % African
American, % Minority (American Indian/Asian/Pacific Islanders)].
b level-2 variables included environmental-, policy-, and market characteristics measured at the state-level: %counties with
broadband access, the American Telemedicine Association telehealth coverage & reimbursement grading, patient consent
policy, interstate telehealth licensure policy, and % rural counties.
c the random slope model included all the variables in Model 3 as fixed-effects and % female patients per day as randomeffects.
d Wald Chi-square values were calculated as (level-2 residual variance/standard error), compared against the critical value of
Chi-square with 1 degree of freedom (3.841).
e The Variance Partition Coefficient (VPC) was calculated with the formula: level-2 residual variance / (level-1 residual
variance + level-2 residual variance), where level-1 residual variance for logistic model = 3.29.
f Model fit was assessed by the Likelihood ratio test = Log likelihood from 2-level model - Log likelihood from single-level
model. A significant Likelihood ratio test indicates the necessity of a 2-level model.
*: p < 0.05; ***: p < 0.001.
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Table 2.2 Descriptions of mental health facilities and Telemental health (TMH) adoption among
mental health facilities in the United States.
All facilities
N
Column %
11,883
100.0

Total

Facilities with TMH
N
%
3,082
25.9

Level-1: Facility characteristics
Type of facility
Care setting
Psychiatric inpatient

1,804

15.2

356

19.7

Residential

1,633

13.7

174

10.7

VAMC

377

3.2

349

92.6

CMHC

2,587

21.8

1,079

41.7

Outpatient

5,088

42.8

1,030

20.2

394

3.3

94

23.9

Private-for-profit

2,069

17.4

380

18.4

Private-non-profit

7,601

64.0

1,714

22.5

Public

2,213

18.6

988

44.6

Multi-setting
Ownership

Religious affiliation
Yes

763

6.4

105

13.8

No

11,091

93.3

2,965

26.7

29

0.2

12

41.4

0-100

3,323

28.0

549

16.5

100-250

1,472

12.4

329

22.4

250-500

1,474

12.4

395

26.8

500-1000

3,684

31.0

1,192

32.4

> 1000

1,930

16.2

617

32.0

1-100

5,398

45.4

938

17.4

100-250

4,340

36.5

1,320

30.4

250-500

1,311

11.0

488

37.2

500-1000

388

3.3

123

31.7

> 1000

446

3.8

213

47.8

Not reported
Annual mental health admissions

Daily volume of patients a

Comprehensiveness of mental health treatments
Treatment focus
Mental health only

8,019

67.5

1,662

20.7

Mental health & Substance Abuse

3,499

29.4

1,217

34.8

365

3.1

203

55.6

1,967

16.6

237

12.0

General health
# of mental health treatment approaches
0-3

b

29

4-5

9,916

83.4

2,845

28.7

0-4

6,668

56.1

1,128

16.9

>5

5,212

43.9

1,954

83.1

0-3

10,541

88.7

2,538

24.1

4-5

1,342

11.3

544

75.9

Yes

7,197

60.6

2,064

28.7

No

4,685

39.4

1,018

21.7

# of mental health services

c, l

# of special mental care programs

d

Non-English services

Quality improvement practice

e

0-3

3,377

28.4

696

20.6

4

3,708

31.2

915

24.7

5

4,757

40.0

1,462

30.7

IT capacity

f, l

Low

2,509

21.1

310

12.4

Moderate

9,006

75.8

2,577

28.6

342

2.9

188

55.0

High

Payer mix
Medicaid
Yes

10,515

88.5

2,635

25.1

No

1,155

9.7

334

28.9

213

1.8

113

53.1

Yes

8,120

68.3

2,339

28.8

No

3,454

29.1

630

18.2

309

2.6

113

36.6

Yes

2,613

22.0

1,131

43.3

No

6,770

57.0

1,350

19.9

Not reported

2,500

21.0

601

24.0

Yes

9,501

80.0

2,694

28.4

No

2,158

18.2

306

14.2

224

1.9

82

36.6

Not reported
Medicare

Not reported
Veteran Health Administration

Any private insurance

Not reported

Case-mix
Any elderly

a

Yes

7,714

64.9

2,372

30.7

No

4,169

35.1

710

17.0

% Females a
0-10%

567

4.8

199

35.1

11-50%

5,872

49.4

1,399

23.8

30

> 50%

5,444

45.8

1,484

27.3

0-20%

9,068

76.3

2,520

27.8

> 20%

2,815

23.7

562

20.0

5,993

50.4

1,617

27.0

5,890

49.6

1,465

24.9

Yes

11,308

95.2

2,895

25.6

No

575

4.8

187

32.5

0-20%

4,327

36.4

933

21.6

20-40%

2,127

17.9

611

28.7

40-60%

1,256

10.6

344

27.4

60-80%

1,536

12.9

354

23.0

Not reported

2,637

22.2

840

31.9

0-50%

9,209

77.5

2,030

22.0

> 50%

302

2.5

265

87.7

2,372

20.0

787

33.2

% African American

a

Any Hispanic/Latino patients

a

Yes
No
Any minority patients

a

% Mental health & substance abuse patients a

Annual % of veteran patients

Not reported

Level-2 variables: Policy characteristics g
ATA telehealth coverage & reimbursement grading h
A

1,362

11.5

427

31.4

B

8,425

70.9

2,098

24.9

C

2,096

17.6

557

26.6

8,127

68.4

2,058

25.3

3,756

31.6

1,024

27.3

Individual state

1,398

11.8

447

32.0

FSMB Compact

2,670

22.5

707

26.5

Special telehealth

1,450

12.2

485

33.4

With exemptions

1,900

16.0

641

33.7

Not required/defined

4,465

37.6

802

18.0

Patient consent

i

Yes
No
Licensure

i

Level-2 variables: Market characteristics

h

Provider shortage j
Low

4,215

35.5

146

16.1

Moderate

3,133

26.4

1,478

27.1

High

4,535

38.2

1,458

34.3

6,114

51.5

1,097

17.9

% rural counties
0-10%

j

31

10-20%
> 20%

3,510

29.5

1,172

33.4

2,259

19.0

813

36.0

Level-2 variables: Environmental resources h
% counties with broadband access k
0-10%

6,112

51.4

1,082

17.7

10-20%

4,391

37.0

1,419

32.3

> 20%

1,380

11.6

581

42.1

Note: The study population included mental health facilities located in the 50 states and the District of Columbia
that responded to the query about telemedicine use and patient characteristics in the 2016 N-MHSS. Facilities in
American Samoa, Guam, Puerto Rico, and Virgin Island were excluded due to insufficient information on telehealth
policies.
a N-MHSS measured total number of patients and patient mix of a facility on a specific day (April 29, 2016).
b Mental health treatment approaches evaluated in N-MHSS included individual psychotherapy,
couples/family/group therapy, cognitive behavioral/dialectical behavioral therapy/behavior modification, integrated
dual disorders treatment, trauma therapy, activity therapy, electroconvulsive therapy, and psychotropic medication.
c Mental health services evaluated in N-MHSS included intensive case/case management/chronic disease/illness
management, integrated primary care services, any counseling, family psychoeducation, education services,
psychosocial rehabilitation services, psychiatric emergency walk-in services, suicide prevention services, peer
support services, screening for tobacco use, smoking cessation services.
d Special mental health programs included mental health programs that is dedicated or designed exclusively for
serious mental illnesses, co-occurring mental and substance abuse disorders, post-traumatic stress disorder,
senior/elderly patients or veterans.
e Quality improvement practice evaluated in N-MHSS included continuing education, case review, outcome followup after discharge, utilization review, and satisfaction surveys.
f The IT capacity was defined as the level of technology involvement in 14 routine facility activities, including
mental health intake, scheduling appointments, assessment/evaluation, treatment planning, client progress
monitoring, discharge, referral, issue/receive lab results, prescribing/dispensing medications, checking medication
interactions, health records, provider collaboration, billing, and satisfaction surveys. The level of technology
involvement was measured by the mean score of all activities rated on a 3-point scale, where “1” denotes no
technology involvement (i.e., rely on paper), “2” indicates partial involvement (i.e., both electronic and paper), and
“3” represents fully involvement (i.e., only electronic).
g environmental-, policy-, and market characteristics were measured for the state where the facility was located.
h the American Telemedicine Association (ATA) has given each state a grade (A, B, C, or F) for the coverage and
reimbursement policies for TH, basing on health plan parity and Medicaid conditions of payment.
i the patient consent policy that requires informed consent before telehealth services and the licensure policy that
requires license for interstate telehealth practice were obtained from the Centers for Connected Health Policy's
(CCHP) annual State Telehealth Laws and Reimbursement Policies Report.
j The percentage counties with primary care physician (PCP) shortage, mental health professional (MHP) shortage,
and the percentage of rural counties were obtained from the Area Health Resources File (AHRF).
k Broadband access was defined as having access to 25Mbps/3 Mbps service; % counties with broadband access in
the locating state were derived from the 2016 Broadband Progress Report.
l Missing data category is not presented due to small sample size (n < 10).

32

Table 2.3 Adjusted odds ratios (AORs) and 95% confidence intervals (95% CI) of facility- and
state-level characteristics on Telemental health (TMH) adoption among mental health facilities in
the United States.
Variables

Model 2

Model 4

Model 5

AOR [95% CI]

AOR [95% CI]

AOR [95% CI]

Level-1: Facility characteristics
Type of facility
Care setting
Residential

1.27 [0.98, 1.63]

1.27 [0.99, 1.64]
***

1.27 [0.99, 1.64]
18.53 [10.66, 32.21] ***

VAMC

18.30 [10.52, 31.82]

CMHC

2.46 [2.03, 2.98] ***

2.46 [2.03, 2.98] ***

2.41 [1.99, 2.93] ***

***

***

1.56 [1.30, 1.88] ***

1.94 [1.43, 2.63] ***

1.94 [1.43, 2.63] ***

Outpatient

1.57 [1.30, 1.89]

Multi-setting

1.94 [1.43, 2.62] ***

18.38 [10.57, 31.97]

***

1.57 [1.31, 1.89]

Psychiatric inpatient

Reference

Ownership
Private-non-profit
Public

1.10 [0.94, 1.29]
1.67 [1.39, 2.01]

1.11 [0.95, 1.29]
***

1.67 [1.39, 2.01]

Private-for-profit

1.10 [0.95, 1.29]
***

1.66 [1.38, 2.00] ***

Reference

Religious affiliation
Yes

0.72 [0.57, 0.91] **

0.72 [0.57, 0.91] **

No

0.72 [0.57, 0.91] **

Reference

Annual mental health admissions
100-250

1.10 [0.92, 1.32]

1.10 [0.92, 1.32]

1.10 [0.92, 1.32]

250-500

1.27 [1.05, 1.52] *

1.27 [1.05, 1.52] *

1.26 [1.05, 1.52] *

500-1000

1.33 [1.12, 1.59] **

1.33 [1.12, 1.58] **

1.33 [1.12, 1.59] **

> 1000

1.39 [1.15, 1.67] **

1.39 [1.15, 1.67] **

1.39 [1.15, 1.68] **

0-100

Reference

Total patients a
100-250

1.11 [0.97, 1.27]

1.11 [0.97, 1.27]

1.12 [0.98, 1.28]

250-500

1.10 [0.91, 1.32]

1.09 [0.91, 1.32]

1.11 [0.92, 1.33]

500-1000

0.86 [0.64, 1.15]

> 1000

1.41 [1.08, 1.83]

0.86 [0.64, 1.14]
*

1.41 [1.08, 1.83]

1-100

0.87 [0.65, 1.16]
*

1.42 [1.09, 1.84] *

Reference
Comprehensiveness of mental health treatments

Treatment focus
Mental health &
Substance Abuse
General services

1.24 [1.10, 1.39] ***

1.24 [1.10, 1.39] ***

1.23 [1.10, 1.38] ***

1.38 [1.00, 1.90] *

1.38 [1.01, 1.90] *

1.38 [1.01, 1.90] *

Mental health only

Reference

# of mental health treatment approaches
4-5

b

2.00 [1.69, 2.37] ***

2.00 [1.69, 2.37] ***
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2.00 [1.69, 2.36] ***

0-3

Reference

# of mental health services

c

1.80 [1.61, 2.00] ***

>5

1.80 [1.61, 2.00] ***

0-4

1.79 [1.61, 2.00] ***

Reference

# of special mental care programs d
4-5

1.15 [0.99, 1.34]

1.15 [0.99, 1.34]

0-3

1.15 [0.99, 1.34]

Reference

Non-English services
1.20 [1.07, 1.35] **

Yes

1.20 [1.08, 1.35] **

No

1.21 [1.08, 1.36] **

Reference
Quality improvement practice

# of Quality Improvement practice e
4

1.13 [0.99, 1.29]

1.13 [0.99, 1.29]

1.13 [0.99, 1.29]

5

1.35 [1.19, 1.53] ***

1.35 [1.19, 1.53] ***

1.35 [1.18, 1.53] ***

0-3

Reference
IT capability

f

Moderate

1.91 [1.65, 2.21]

***

1.91 [1.65, 2.22] ***

1.90 [1.64, 2.20] ***

High

2.93 [2.13, 4.03] ***

2.93 [2.13, 4.04] ***

2.89 [2.10, 3.98] ***

Low

Reference
Payer mix

Medicaid
Yes

1.13 [0.91, 1.41]

1.13 [0.91, 1.41]

No

1.12 [0.90, 1.40]

Reference

Medicare
1.25 [1.08, 1.45] **

Yes

1.25 [1.08, 1.45] **

No

1.26 [1.09, 1.47] **

Reference

Veteran Health Administration
1.37 [1.21, 1.56] ***

Yes

1.37 [1.21, 1.56] ***

No

1.36 [1.20, 1.55] ***

Reference

Private
1.51 [1.27, 1.79] ***

Yes

1.50 [1.27, 1.78] ***

No

1.47 [1.24, 1.74] ***

Reference
Case-mix

% of female patients a
11-50%

0.77 [0.57, 1.05]

0.77 [0.57, 1.05]

0.78 [0.57, 1.06]

> 50%

0.83 [0.61, 1.13]

0.83 [0.61, 1.13]

0.83 [0.61, 1.14]

0-10%
Having elderly patients
Yes

Reference
a

1.17 [1.03, 1.32] *

1.16 [1.03, 1.32] *

No

Reference

% of African American patients
> 20%

1.16 [1.02, 1.31] *

a

0.74 [0.65, 0.85] ***

0.74 [0.65, 0.85] ***
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0.74 [0.65, 0.85] ***

0-20%

Reference

Having Hispanic/Latino patients
Yes

a

1.09 [0.98, 1.22]

1.10 [0.98, 1.22]

No

1.10 [0.98, 1.23]

Reference

Any minority patients a
Yes

1.25 [1.00, 1.57]

1.24 [0.99, 1.56]

No

1.24 [0.99, 1.56]

Reference

% of MHSA patients a
20-40%

1.03 [0.89, 1.19]

1.03 [0.89, 1.19]

40-60%

0.95 [0.80, 1.14]

0.95 [0.80, 1.14]
*

> 60%

0.83 [0.70, 0.98]

Not reported

0.81 [0.67, 0.98] *

1.03 [0.89, 1.19]
0.96 [0.81, 1.14]
*

0.83 [0.70, 0.98] *

0.81 [0.67, 0.98] *

0.81 [0.67, 0.98] *

0.83 [0.70, 0.98]

0-20%

Reference

Annual % of veteran patients
> 50%

2.74 [1.65, 4.56] ***

2.75 [1.65, 4.57] ***

2.75 [1.65, 4.57] ***

Not reported

1.24 [1.02, 1.50] *

1.24 [1.02, 1.50] *

1.24 [1.02, 1.50] *

0-50%

Reference
Level-2: Policy characteristics g

ATA telehealth coverage & reimbursement grading h
A

-

1.02 [0.47, 2.21]

0.57 [0.31, 1.05]

B

-

0.91 [0.49, 1.68]

0.74 [0.46, 1.19]

C

Reference

Patient consent i
Yes

-

0.82 [0.52, 1.29]

No

0.84 [0.61, 1.17]

Reference

Licensure i
Individual state

-

1.70 [0.82, 3.56]

FSMB Compact

-

1.63 [0.93, 2.86]

Special telehealth

-

2.28 [1.02, 5.06]

With exemptions

-

1.37 [0.73, 2.58]

Not required/defined

1.54 [0.88, 2.72]
1.05 [0.69, 1.59]
*

2.24 [1.16, 4.32] *
1.09 [0.67, 1.78]

Reference
Level-2: Market characteristics g

Provider shortage j
High

-

Moderate

-

Low

-

0.90 [0.53, 1.54]

-

1.41 [0.83, 2.39]

Reference

% rural counties j
10-20%

-

-

2.09 [1.33, 3.29] **

> 20%

-

-

2.36 [1.34, 4.18] **

0-10%

Reference
Level-2: Environmental resources g
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% counties with broadband access k
10-20%

-

-

1.02 [0.65, 1.62]

> 20%

-

-

1.63 [0.92, 2.87]

0-10%

Reference

Note: The study population included mental health facilities located in the 50 states and the District of Columbia that
responded to the query about telemedicine use and patient characteristics in the 2016 N-MHSS. Facilities in American Samoa,
Guam, Puerto Rico, and Virgin Islands were excluded due to insufficient information on telehealth policies.
a N-MHSS measured total number of patients and patient mix of a facility on a specific day (April 29, 2016).
b Mental health treatment approaches evaluated in N-MHSS included individual psychotherapy, couples/family/group therapy,
cognitive behavioral/dialectical behavioral therapy/behavior modification, integrated dual disorders treatment, trauma therapy,
activity therapy, electroconvulsive therapy, and psychotropic medication.
c Mental health services evaluated in N-MHSS included intensive case/case management/chronic disease/illness management,
integrated primary care services, any counseling, family psychoeducation, education services, psychosocial rehabilitation
services, psychiatric emergency walk-in services, suicide prevention services, peer support services, screening for tobacco use,
smoking cessation services.
d Special mental health programs included mental health programs that is dedicated or designed exclusively for serious mental
illnesses, co-occurring mental and substance abuse disorders, post-traumatic stress disorder, senior/elderly patients or veterans.
e Quality improvement practice evaluated in N-MHSS included continuing education, case review, outcome follow-up after
discharge, utilization review, and satisfaction surveys.
f The IT capacity was defined as the level of technology involvement in 14 routine facility activities, including mental health
intake, scheduling appointments, assessment/evaluation, treatment planning, client progress monitoring, discharge, referral,
issue/receive lab results, prescribing/dispensing medications, checking medication interactions, health records, provider
collaboration, billing, and satisfaction surveys. The level of technology involvement was measured by the mean score of all
activities rated on a 3-point scale, where “1” denotes no technology involvement (i.e., rely on paper), “2” indicates partial
involvement (i.e., both electronic and paper), and “3” represents fully involvement (i.e., only electronic).
g environmental-, policy-, and market characteristics were measured for the state where the facility was located.
h the American Telemedicine Association (ATA) has given each state a grade (A, B, C, or F) for the coverage and
reimbursement policies for TH, basing on health plan parity and Medicaid conditions of payment.
i the patient consent policy that requires informed consent before telehealth services and the licensure policy that requires
license for interstate telehealth practice were obtained from the Centers for Connected Health Policy's (CCHP) annual State
Telehealth Laws and Reimbursement Policies Report.
j The percentage counties with primary care physician (PCP) shortage, mental health professional (MHP) shortage, and the
percentage of rural counties were obtained from the Area Health Resources File (AHRF).
k Broadband access was defined as having access to 25Mbps/3 Mbps service; % counties with broadband access in the
locating state were derived from the 2016 Broadband Progress Report.
* p < 0.05; ** p < 0.01; *** p < 0.001.
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CHAPTER 3
3 Telemental Health Use Among Adults with Mental Health Conditions Enrolled in A
Nationwide Commercial Health Insurance
3.1 Abstract
Objective: To examine telemental health (TMH) use and associated patient and statelevel factors among adults with mental health conditions (MHCs). Data sources: Linked deidentified claims (01/01/2010 – 06/30/2017) from Optum Clinformatics ® DataMart, Area Health
Resources File, and the National Mental Health Services Survey were used. Study design: This
study utilized a retrospective, dynamic cohort of adults with MHCs (N = 248,060). Data
collection/methods: MHCs were identified using diagnostic codes, and TMH use was ascertained
using procedure codes derived from claims data. Multilevel logistic regression was used to assess
the association of TMH use with patient- and state-level factors. Principal findings:
Approximately 16 in 10,000 adults with MHCs used TMH. Patient characteristics associated
with TMH use included younger age, higher monthly out-of-pocket expenditures, past mental
health specialist visits, and diagnosis of a severe MHC (Adjusted Odds Ratio (AOR): 1.42-9.46).
TMH use varied widely across states and was significantly and positively associated with high
mental health provider shortages and high TMH capacity. Conclusions: TMH use was low
among commercially insured MHC patients. TMH use was mainly driven by patients’ need,
provider shortages, and TMH capacity, suggesting that expanding TMH capacity could help
alleviate the unmet need for mental health services.
3.2 Introduction
Mental health conditions (MHCs) affect 43.8 million adults in the United States (US).101
MHCs can have a devastating impact on all aspects of an individual’s life and are the costliest
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health conditions with an annual cost of $201 billion on the population level.101,102 Despite the
availability of effective mental health (MH) treatments, only 43% of US adults with MHCs
received mental health services in 2016.103 The longstanding shortage of mental health providers
is of a significant contributor to the unmet needs for mental health care, especially in
underserved rural areas.104,105 It is reported that about 77% of US counties had a severe shortage
of mental health professionals (e.g., psychiatrists, psychologists, and social workers).104
The unresolved shortage of mental health providers has incentivized payers and providers
to find innovative alternative care delivery models to supplement in-person care. In this context,
Telemental health (TMH), broadly defined as the delivery of MH services remotely, has been
increasingly considered as a part of mental health care.106 TMH has the advantages of expanding
patient access to existing providers, decreasing patients’ indirect costs (i.e., travel time and cost),
and potentially reducing the stigma associated with visiting mental health facilities.30 Results
from randomized trials have demonstrated that TMH in various modalities (e.g., internet, phone,
video-conferencing) is comparable or even superior to in-person care for evaluating and treating
patients with MHCs, including those with severe MHCs, such as schizophrenia.50,51,107
Recognizing the potential for TMH to remove access-related barriers to treatment,
federal, state, and local governments have made substantial efforts to increase TMH services in
recent years.40 However, only a few studies have examined TMH use among adults with MHCs
in real-world settings using recent data. One study analyzing 2008 and 2009 Medicaid claims
reported very low (< 0.1%) TMH use and high state-level variations due to differences in
coverage and reimbursement policies for TMH across states.41 Notable variations in TMH use
were also reported in a study analyzing 2004-2014 claims data of Medicare beneficiaries with
MHCs, who had the same TMH coverage and reimbursement policies.42 While these studies
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illustrated the role of reimbursement policies in TMH use, they also highlighted the wide
variation in TMH use among states, despite having the same reimbursement and coverage for
TMH services. This finding suggests that patient characteristics and state-level factors may also
contribute to TMH use.
Little is known about patient-level factors and other state-level factors associated with
TMH use. Previous studies have reported that TMH use was significantly associated with
younger age, having any disability, and living in a poor community.43,44 Health plan
characteristics (e.g., out-of-pocket expenditures45), factors that may increase the need for
TMH/MH services (e.g., previous treatment seeking,46 polypharmacy 47), and environmental
capacities that allow TMH use were not explored. Furthermore, there is evidence showing that
private payers are more likely to be billed for telehealth services than public payers.38 While
commercial insurance provides an important source of health coverage for adults with MHCs, 48
knowledge about TMH use among commercially insured adults with MHC is limited. Although
TMH has been covered for almost all MH services from various providers (e.g., psychiatrists,
social worker, physicians),49 how TMH is used in various MH services and who is delivering
TMH in real-world practice remained unknown. Such knowledge is vital to inform health
insurers and healthcare policymakers how to better incorporate TMH in delivering mental health
services into real-world healthcare settings.
In this study, we examined TMH use, explored the role of TMH use in delivering MH
service, and assessed the association of patient and state-level factors to TMH use in adults with
MHCs using linked claims data from a large U.S. commercial plan.
3.3 Methods
Data sources
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This study used linked data from several sources: 1) de-identified 10% sample drawn
from the Optum Clinformatics ® DataMart (Optum Clinformatics ®, Eden Prairie, MN, USA)
from 1st January 2010 through 30th June 2017; 2) the 2016-2017 Area Health Resources File
(AHRF); and 3) the 2010 – 2016 National Mental Health Services Survey (N-MHSS). Optum
Clinformatics ® provides de-identified paid medical and prescription claims and enrollment
information for individuals enrolled in a large US commercial health insurance company, which
has geographically diverse enrollment across all 50 states and the District of Columbia (DC).108
The AHRF includes data on healthcare providers, population characteristics and environment at
the county, state and national levels from over 50 data sources.109 The N-MHSS is the only
source of national and state-level data on mental health service delivery system for all known
public and private mental health treatment facilities in the US. 78 Data from these three sources
were linked using state identifiers.
Study design
This study employed a retrospective, dynamic cohort design with a baseline and followup period. The study cohort consisted of adults with MHC conditions. Adults with any MHC
were identified during a calendar year by one inpatient claim or two or more outpatient claims
with a primary or secondary diagnosis of schizophrenia, bipolar disorder, major depressive
disorder and other MHCs using the International Classification of Diseases, Ninth or Tenth
Revision (ICD9/ICD10) codes (ICD9: 291-292, 295 – 316; ICD10: F10-F99).42 Study cohorts
were identified for each year and pooled together. For adults with MHC who were identified in
multiple years, the first observation was kept for subsequent analyses.
TMH use was assessed in the 12 months after first observed MHC diagnosis. For TMH
users, the first observed TMH use date was considered as the index date; this date was used to
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define a baseline period. A pseudo-index date was randomly selected from all MH services dates
for adults without a record of TMH use. The six months before the index/pseudo-index dates was
defined as the baseline period.
Study sample
The study sample comprised adults at least 18 years of age at baseline) who were: 1)
diagnosed with any MHC in a calendar year between 2010 and 2016; 2) had at least two MH
service encounters during the study period; and 3) were continuously enrolled in the insurance
plan throughout the baseline and 12-month follow-up period. The cohort identification process is
illustrated in Figure 3.1. All MH service encounters were identified with procedure codes
(Appendix 7.1).42
Measures
Outcome variable: Any TMH Use
Any TMH use was identified from MH service claims using Healthcare Common
Procedure Coding System (HCPCS)/ Current Procedural Terminology (CPT) codes (“0188T”,
“0189T”, “G0406 – 0408”, “G0425 – 0427”, “G0459”) and/or modifiers appended with the
procedure codes (“GT”, “GQ”, “95”).42,49 Adults with MHCs with no record of TMH use were
considered non-users. We also examined annual TMH visit rate, which was calculated as the
number of TMH visits per 1,000 adults with MHCs from 2010 to 2017. The type of MH services
delivered via TMH/in-person was determined by HCPCS/CPT codes and modifiers, and the type
of provider who delivered TMH/in-person MH services was identified with provider category
codes.
Explanatory variables:
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The explanatory variables were selected based on the common and unique constructs
from determinants of health model proposed by Wilkinson and Marmot,72 the Telehealth
Research and Policy Framework proposed by a multidisciplinary group of experts,73 and a
comprehensive review of the literature.42,110 Factors that could affect TMH use can be grouped
into several domains, including 1) biological factors (age and sex); 2) health insurance
characteristics [types of health insurance (Medicare Advantage/others), types of health plan
(Health Maintenance Organization/Preferred Provider Organization/Point of Service/Fee-forservice), average monthly out-of-pocket (OOP) expenditures for medical services]; 3) need
factors that may increase the need for TMH [severity of MHCs, number of physical chronic
conditions, the presence of polypharmacy (> 5 drug classes in a 90-day period),111 obesity, and
any substance use disorders (i.e., alcohol, tobacco, drug), and in-person mental health specialist
visits]; and 4) environmental factors [state-level poverty, rurality, mental health provider
shortages (MHPS), and TMH capacity]. We also adjusted for the year of TMH use to account for
policies and other environmental factors that may change over time.
State-level poverty, rurality, and MHPS were measured as the average percentage, within
each state, of counties in poverty, rural counties, and counties with MHPS; all percentages were
derived using AHRF data. TMH capacity was defined as the average percentage of mental health
facilities adopting the use of telemedicine within a state, using 2010 – 2016 N-MHSS data. To
facilitate interpretation of the relationship between state-level factors and TMH use by patients,
we analyzed environmental factors by comparing the lower and upper 50th percentiles.
Patient-level factors were derived using the medical claims, pharmacy claims, and
enrollment files from Optum Clinformatics ®. The severity of MHCs was determined with an
algorithm developed by researchers from the Healthcare Cost and Utilization Project.112 The
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chronic physical conditions examined were based on a list of 13 chronic conditions (i.e., arthritis,
asthma, coronary artery disease, cardiac arrhythmias, congestive heart failure, chronic kidney
disease, chronic obstructive pulmonary disease, dementia and related disorders, diabetes,
hypertension, hyperlipidemia, osteoporosis, stroke) by the Multiple Chronic Conditions working
group.113 All the patient-level factors were measured during the baseline period.
Statistical analyses
The percentage of TMH users were calculated for all adults with MHCs and within
subgroups defined by patient-level and state-level characteristics. Several multilevel logistic
regressions were constructed to identify factors associated with TMH use among adults with
MHCs, where patients (Level-1) were nested within states (Level-2). Table 2 outlines the modelbuilding process. Level-1 variables included health insurance characteristics as well as biological
and need factors, while Level-2 variables included all environmental factors. State-level
variations in TMH use were evaluated with Wald chi-square tests and quantified by Variance
Partition Coefficients (VPCs). The likelihood-ratio (LR) test was employed to evaluate the
significance of two-level models versus (vs.) single-level models. As Medicare Advantage only
covered telehealth for those in underserved areas, subgroup analyses were performed for adults
with MHCs enrolled in Medicare Advantage plans who lived in underserved states (i.e., states
with high level of rurality or shortage of providers). All analyses were conducted using SAS 9.4
(SAS Institute Inc., Cary, NC) and Stata 14 (StataCorp LLC, College Station, TX).
3.4 Results
Sample description
A total of 248,060 adults with MHC were identified. As presented in Table 1, the most
prevalent MHC was anxiety disorders (42.5%). Almost one-third (32.2%) of the study sample
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had at least one serious MHC, including schizophrenia (1.5%), bipolar disorder (7.7%), and
major depressive disorder (24.8%). The sample was predominantly female (61.5%), with a mean
age of 49.2 years [Standard deviation (SD) = 18.4].
At baseline, the majority (77.9%) of the study sample were enrolled in non-HMO plans
such as Preferred Provider Organizations, Point of Services, and Fee-for-Services plans. About
one-third (32.6%) of the cohort had received at least one MH service for a severe MHC
diagnosis, and 21.9% had visited a mental health specialist. About 16.9% had been diagnosed
with tobacco/alcohol use disorders, 5.8% with drug use disorders, and 8.2% with obesity.
Polypharmacy was present in 27.8% of MHC patients. Nearly two-fifths (38.9%) of MHC
patients were from states with high levels of poverty; the majority were from states with high
levels of rurality (58.2%) or MHPS (54.6%). Over half (56.5%) of adults with MHCs in our
study sample resided in states with a low TMH capacity (Table 1).
Across states, variation in patient characteristics and environmental factors was
substantial. For example, the percentage of adults with severe MHCs varied from 20% to 45%,
and MA-enrollment ranged from 0% to 94%. Percentages of rural counties and counties with
MHPS varied widely, ranging from 0% to 91.3% and 0 to 100%, respectively. TMH capacity
was as low as 1.8% in Connecticut and as high as 61.4% in North Dakota.
Description of MHS delivered by TMH and in-person among TMH users
Almost all TMH services (95.3 %) were delivered via interactive audio/video
telecommunications systems. Across various MHS categories, TMH played an essential role in
the delivery of outpatient/inpatient consultation and pharmacological management, with 94.7%
and 53.8% of these procedures administered via TMH, respectively (Figure 3.2). Among all the
MH services delivered by TMH, the most commonly used services were routine office visits
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(40.5%), initial hospital inpatient care (17.8%), and pharmacological management (16.6%). By
contrast, the most prevalent in-person MH visits were for psychotherapy (30.5%). Regarding the
type of providers who delivered MHS, most TMH services were delivered by psychiatrists
(62.3%) and social workers/counselors (21.8%), whereas in-person MHS were delivered by a
range of providers, including psychiatrists (24.5%), social workers/counselors (21.2%), family
physicians/internalist (11.6%), and psychologists (11.3%).
Description of TMH users among adults with MHCs
From 2010 to 2017, the percentage of TMH users among adults with MHC had increased
by 23-fold [0.03% to 0.69%], and the annual rate of TMH visits had increased by almost eightfold [1.1 to 8.7 visits/1,000 adults with MHCs]. Overall, only 0.16% of adults with MHC (N =
385) had ever used TMH in the 12 months after MHC diagnosis. The percentage of TMH users
varied significantly across all patient-level characteristics, except for sex (Table 1). TMH use
was highest (1.62%) among adults with schizophrenia, and lowest (0.03%) among MHC patients
enrolled in non-MA plans. TMH use also varied across states. States with high TMH capacities
had the highest TMH use (0.24%), whereas states with low MHPS had the lowest use (0.08%). A
total of 18 states (e.g., Alaska, Connecticut, Delaware) had zero TMH use, most of which were
clustered at the Northeast. TMH use was highest in North Dakoda (1.16%), followed by
Tennessee (0.69 %) and Indiana (0.68%).
The association of Patient-level factors with TMH use among adults with MHCs
Table 2 presents the results of our multilevel logistic regression analyses. In the fully
adjusted model (Model 4), age, all insurance characteristics, and most need factors were
significantly associated with TMH use. Specifically, age was significantly and inversely
associated with TMH use [Adjusted Odds Ratio (AOR) per year increment: 0.98, 95%
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Confidence Interval (95%CI): 0.97-0.99]. Furthermore, higher monthly OOP expenditures were
associated with higher odds of TMH use [(AORs: 1.48-1.89, p < 0.01)]. Need factors associated
with TMH use included a history of services for a severe MHC diagnosis [AOR (95%CI): 2.14
(1.66-2.76)], in-person visits to mental health specialists [AOR (95%CI): 9.46 (7.39-12.11)], and
polypharmacy [AOR (95%CI): 1.42 (1.10-1.83)] at baseline.
State-level factors associated with TMH use among adults with MHCs
Results from likelihood ratio tests indicated significant variation in TMH use across
states (Table 2). Adding state-level factors to the regression model resulted in a reduction in
state-level variance, with VPC values declining from 0.43 to 0.30). State-level MHPS and TMH
capacity were significantly associated with TMH use: MHC patients residing in states with high
levels of MHPS [AOR (95%CI): 4.65 (1.72 – 12.60)] and states with high TMH capacity [AOR
(95%CI): 2.62 (1.09 – 6.28)] were more likely to use TMH than were those residing in states
with low levels of MHPS and TMH capacity, respectively (Table 2).
Secondary Analysis: Patient- and State-level factors associated with TMH use among MA
enrollees with MHC living in underserved states
As TMH use was much higher in the MA subgroup, we assessed correlates of TMH
utilization among MA enrollees in separate analyses. Among 61,861 MA enrollees with MHC
lived in underserved states, 0.47% used TMH. Results from multilevel regressions indicated
associations of TMH use to patient- and state-level factors that were similar to those observed in
the pooled sample. TMH use was more likely among MA enrollees with MHCs who were
younger than 65 years [AOR(95%CI): 1.99 (1.52-2.60)], who had higher monthly OOP
payments (AORs: 1.39-1.57, p < 0.05), who had visited any mental health specialist [AOR
(95%CI): 9.86 (7.40-13.14)], who had received a diagnosis of any severe MHC [AOR (95%CI):

46

1.83 (1.36-2.46)], and who resided in states with high MHPS [AOR (95%CI): 4.29 (1.79-10.29)].
However, TMH capacities and polypharmacy were not significantly associated with TMH use
(Table 3).
3.5 Discussion
Overall, our study examined the role of TMH in delivering mental health services and
identified patient and state-level factors associated with TMH use in a large commercially
insured adult population with MHCs. Approximately 16 in 10,000 adults with MHC and 47 in
10,000 of those enrolled in MA plans and lived in underserved states used TMH in a given year,
respectively. We found that most TMH services were delivered by psychiatrists, suggesting
TMH may have been used primarily for increasing access to mental healthcare specialists. This
may reflect the ongoing severe shortage of psychiatrists and the growing demand for mental
healthcare specialists in the US.15,54 Given that the American Psychiatric Association (APA) had
coordinated with the American Telemedicine Association (ATA) to develop a clinical guideline
on videoconferencing in mental health,114 it is also plausible that psychiatrists may differ from
other mental health providers in training, which leads to a higher uptake of TMH in their
practice. Future efforts to expand TMH services may target allied mental health professionals
such as psychologists, social workers, counselors, and nurse practitioners, who play important
roles in delivering in-person mental health services to patients with MHCs.
The role of TMH in delivering MH services varied by the type of service. TMH has
mostly been used for outpatient/inpatient consultations (94.7%) and pharmacological
management (53.8%). The extensive use of TMH for providing consultations may be due to the
shortage of psychiatrists in the US.15 Consultations via TMH can make psychiatry services
available to patients with MHCs, regardless of time and geographical barriers.115
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Pharmacological management is an essential part of mental healthcare. Given the increasingly
important role that pharmacists are playing in comprehensive medication management in
collaborative care models, additional research is needed to explore the feasibility, acceptability,
and outcomes of pharmacist-delivered, TMH based medication management.116
On the other hand, the delivery of psychotherapy using TMH was rare despite growing
evidence supporting the effectiveness of psychotherapy delivered via TMH using a range of
modalities.52,117,118 This might be due to a lack of clinician confidence and experience in
delivering Tele-psychotherapy.31,117,119 A recent systematic review of studies comparing the
therapeutic alliance of Tele vs. in-person psychotherapy suggested that guidelines and training
on TMH delivery of psychotherapy could increase clinicians’ comfort and confidence.118 The
newly released guidelines on videoconferencing-based TMH services by the American
Psychiatric Association and American Telemedicine Association may help to increase the use of
TMH for providing psychotherapy in the future.114
Overall, TMH use was significantly associated with patient age, health insurance
characteristics, and severity of MHC. We found that TMH use was more likely among patients
with MHCs of younger age and among MA enrollees who were less than 65 years old, consistent
with previously reported results from studies of Medicaid and Medicare populations.41,42
Although there is evidence that telehealth programs are well-accepted by elderly populations,120
home-based telehealth has not been widely covered by Medicare or most commercial plans,
potentially limiting TMH use by older adults. Efforts that facilitate home-based TMH services,
including expanding high-speed internet coverage and reimbursement coverage of Tele-home
health, may help increase TMH use among elderly patients.121
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Another interesting finding is that higher monthly out-of-pocket (OOP) expenditures
were associated with higher odds of TMH use in both the pooled sample and MHC patients in
MA plans. Higher OOP expenditures have been perceived as significant barriers to healthcare.45
While the insurance plans required some OOP costs (i.e., co-pay, coinsurance, deducible) for
patients using TMH and in-person MH services, patients bearing higher direct healthcare costs
might choose TMH to reduce their indirect healthcare costs (i.e., traveling time and costs).122,123
Our results indicated that patients with greater mental health care needs were more likely
to use TMH services. TMH use was most prevalent among patients with schizophrenia.
Furthermore, having any severe MHC diagnosis at baseline was associated with higher odds of
TMH use. This might be because patients with severe MHCs have a critical need for
pharmacological and psychosocial treatments, as well as specialist care.58 It has been well
documented that geographical barriers such as longer travel distance to care are negatively
associated with receiving mental health treatments.124 Limited access to care due to geographical
barriers may have a greater impact on healthcare outcomes of adults with severe MHCs as
compared to those with less severe conditions.125 TMH can facilitate access to mental health
specialist for these patients, especially those with limited or no access to mental health
specialists.54 Furthermore, our finding that TMH use was more likely among patients with a
history of any specialist visits at baseline indicated that TMH might help patients with MHCs
continue specialist care with follow-up visits via TMH.
We found that TMH use was much higher among patients with MHCs who were enrolled
in MA plans than those who were not. It is surprising that MA enrollees had higher TMH use
because non-MA insurance plans do not limit TMH coverage to patients living in underserved
rural areas, while MA plans do limit coverage. It is plausible that MHC patients in MA plans had
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more severe conditions (Supplemental table) and therefore perceive more need for mental health
services in general than those who were not in MA plans.
It is worth noting that polypharmacy was associated with higher odds of TMH use among
all adults with MHCs, but not among those enrolled in MA plans. Although pharmacological
management was one of the most commonly used TMH services, Medicare covers this service
only as part of inpatient care. Given that polypharmacy is more prevalent in the elderly
population, as compared to their younger counterparts, expanding Medicare TMH coverage for
pharmacological management in outpatient settings may increase TMH use by this population.
TMH use varied significantly across states despite similar TMH coverage and
reimbursement policies. Results from multilevel analyses revealed that this inter-state variation
could be partially explained by state-level shortages of mental health providers and differences in
TMH capacity among mental health facilities. Patients from states with greater shortages or
higher TMH capacity were significantly more likely to use TMH, than those without such an
environment. These findings suggest that increasing TMH capacity in health facilities is an
essential step in encouraging TMH use among patients with MHCs.
Limitations
The study has several strengths, including our large sample size and the identification of
factors contributing to state-level variation in TMH use. We derived study cohorts from claim
data of a geographically diverse population from all 50 states and DC, which supports the
examination of state-level variation in TMH use across the nation.108 Furthermore, we used
linked, nation-wide data from three databases, permitting us to capture a wide array of
information regarding both patient- and state-level factors. However, several limitations should
also be noted. First, we only had access to claims till June 30th, 2017, potentially leading to
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underestimation of TMH usage this year. Second, MA only covers TMH for those in
underserved rural areas. Due to the lack of information on personal residency such as zip codes,
the percentage of TMH users among MA enrollees with MHCs in our study may underrepresent
the utilization of TMH in this population. Third, the results may be affected by unmeasured
factors (e.g., race/ethnicity, education levels, patient and provider preferences) that were not
captured in our data. Furthermore, as claims data do not include clinical information on disease
severity (e.g., symptoms, functioning status), the number of patients with severe MHCs may
have been underestimated due to our reliance on diagnostic codes. Another limitation is that
subgroup analyses of TMH use among patients with a specific MHC, or among those who were
only privately insured was not possible due to limited sample sizes of users in these groups.
Finally, although we examined TMH use among enrollees of one of the largest commercial plans
in the country, our results may not be generalizable to MHC patients insured by other
commercial plans.
3.6 Conclusion
In summary, TMH use among adults with MHCs was low in this study of a large,
commercially insured population. Psychotherapy delivered via TMH was rare relative to those
delivered in-person. Substantial state-level variation in TMH use was observed even in the
presence of similar reimbursement and coverage policies. Our results suggest that current TMH
use among MHC patients were driven mainly by a greater need to access mental health
specialists. TMH use was also particularly low among certain patient subgroups, suggesting that
targeted efforts are needed to encourage TMH use in these populations. Collaborative efforts by
payers and providers, particularly those that could expand TMH capacity in healthcare settings,
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could increase the availability of TMH in mental health care delivery, and thus, increase access
to mental healthcare services for patients with MHCs.
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Table 3.1 Description of adults with mental health conditions (MHC) and percentages of
Telemental health (TMH) users among adults with MHC.
Adults with MHCs
N
Column %
248,060
100.00
79,861
32.19
3,639
1.47
19,010
7.66
61,571
24.82
105,501
42.53

All adults with MHC
Any serious MHC
Schizophrenia
Bipolar
Major depressive disorders
Any anxiety disorders
Year of TMH use
2010
2011
2012
2013
2014
2015
2016
2017

43,256
17.44
36,680
14.79
34,780
14.02
31,761
12.80
31,847
12.84
34,111
13.75
31,827
12.83
3,798
1.53
†
Patient-level: Biological factors
Age [mean (standard deviation)], years
49.2 (18.4)
Sex
Female
152,498
61.49
Male
95,524
38.51
Patient-level: Health insurance characteristics †
Type of insurance
Medicare Advantage (MA)
70,466
28.41
Non-MA
177,594
71.59
Plan type
Health Maintenance Organization (HMO)
54,799
22.09
Non-HMO
193,261
77.91
Monthly out-of-pocket expenditures
Zero
146,379
59.01
st
nd
Low (1 & 2 Quartile)
39,673
15.99
High (3rd & 4th Quartile)
62,008
25.00
†
Patient-level: Need factors
‡
Any severe MHC
Yes
80,860
32.60
No
167,200
67.40
Any mental health specialist visit
Yes
54,397
21.93
No
193,663
78.07
§
Number of physical chronic conditions
None
117,389
47.32
1-2
49,445
19.93
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TMH users%
N (%)
385 (0.16)
295 (0.37)
59 (1.62)
104 (0.55)
178 (0.29)
200 (0.19)
11 (0.03)
24 (0.07)
25 (0.07)
41 (0.13)
49 (0.15)
80 (0.24)
129 (0.41)
26 (0.69)
58.1 (15.8)
233 (0.15)
152 (0.16)

325 (0.46)
60 (0.03)
174 (0.32)
211 (0.11)
131 (0.09)
104 (0.26)
150 (0.24)

295 (0.37)
90 (0.05)
280 (0.52)
105 (0.05)
76 (0.07)
72 (0.15)

3 or more
81,226
32.74
237 (0.29)
¶
Polypharmacy
Yes
69,039
27.83
210 (0.30)
No
179,021
72.17
175 (0.10)
Any tobacco/alcohol use disorder
Yes
41,804
16.85
86 (0.21)
No
206,256
83.15
299 (0.15)
Any drug use disorder
Yes
14,435
5.82
71 (0.29)
No
233,625
94.18
314 (0.14)
Obesity
Yes
20,251
8.16
65 (0.32)
No
227,809
91.84
320 (0.14)
State-level: Environmental factors
Poverty ††
Low (1st & 2nd Quartile)
151,530
61.09
207 (0.14)
rd
th
High (3 & 4 Quartile)
96,530
38.91
178 (0.18)
Rurality ††
Low (1st & 2nd Quartile)
103,685
41.80
125 (0.09)
rd
th
High (3 & 4 Quartile)
144,375
58.20
260 (0.25)
Mental health provider shortage ††
Low (1st & 2nd Quartile)
112,535
45.37
115 (0.09)
High (3rd & 4th Quartile)
135,525
54.63
270 (0.24)
‡‡
TMH capacity
1st Quartile
64,948
26.18
24 (0.04)
2nd Quartile
75,345
30.37
99 (0.13)
rd
3 Quartile
50,319
20.29
155 (0.31)
4th Quartile
57,448
23.16
107 (0.19)
†
Note: all patient-level factors were measured in the six-month period before index dates based on deidentified claims of Optum Clinformatics ® DataMart. The first TMH use date was used as index date
for users and a pseudo-index date was randomly selected from all mental health service dates among
non-users.
‡
the severity of mental health conditions was measured with a algorithm developed by researchers
from the Healthcare Cost and Utilization Project based on diagnostic codes from claims.
§
chronic conditions examined included arthritis, asthma, coronary artery disease, cardiac arrhythmias,
congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, dementia and
related disorders, diabetes, hypertension, hyperlipidemia, osteoporosis, stroke.
¶
polypharmacy was defined as having more than five medications from different therapeutic classes
in the 90 days before index date.
††
poverty, rurality, and mental health provider shortage were measured as average percentages of
counties under qualified for each condition from 2010-2016 based on data from the 2016-2017 Area
Health Resources File.
‡‡
TMH capacity was measured as average percentages of mental health facilities with telemedicine
from 2010-2016 based on data from the 2010-2016 National Mental Health Services Survey.
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Table 3.2 Results of multilevel logistic regressions on Telemental health use (yes/no) among adults
with mental health conditions (MHCs).

Year of TMH use

Model 1
AOR (95%CI)
1.45 [1.37, 1.53] ***

Model 2
AOR (95%CI)
1.45 [1.37, 1.53] ***

Model 3
AOR (95%CI)
1.45 [1.37, 1.53] ***

Model 4
AOR (95%CI)
1.44 [1.36, 1.53] ***

Patient-level: Biological factors †
Age (years)
Sex
Female
Male

0.98 [0.97, 0.99] ***

0.98 [0.97, 0.99] ***

0.98 [0.97, 0.99] ***

0.98 [0.97, 0.99] **

1.16 [0.93, 1.44]

1.16 [0.94, 1.44]

1.16 [0.94, 1.43]

1.16 [0.94, 1.44]

Patient-level: Health insurance characteristics †
Type of plan
MA

15.70
[10.66, 23.11] ***

Non-MA
Plan type
HMO
1.25 [0.97, 1.62]
Non-HMO
Monthly out-of-pocket expenditures ‡
Low
1.48 [1.13, 1.95] **
High

1.89 [1.45, 2.45]

***

15.72
[10.68, 23.14] ***

15.92
[10.81, 23.45] ***

15.94
[10.83, 23.47] ***

1.25 [0.96, 1.61]

1.25 [0.96, 1.61]

1.27 [0.98, 1.65]

1.48 [1.12, 1.94] **

1.48 [1.13, 1.95] **

1.48 [1.13, 1.95] **

1.88 [1.45, 2.45]

***

1.89 [1.45, 2.45]

***

1.89 [1.45, 2.46] ***

Zero
Patient-level: Need factors †
Any severe MHC §
Yes

2.14
[1.66, 2.76] ***

2.14
[1.66, 2.76] ***

No
Any in-person mental health specialist visit
Yes
9.39 [7.34, 12.03]
9.41 [7.35, 12.04] ***

2.14
[1.66, 2.76] ***

2.14
[1.66, 2.76] ***

9.45 [7.38, 12.10] ***

9.46 [7.39, 12.11] ***

***

No
Number of physical chronic conditions ¶
1-2
3 or more
None
Polypharmacy ††
Yes

1.32 [0.93, 1.87]
1.35 [0.97, 1.87]

1.32 [0.93, 1.87]
1.35 [0.97, 1.88]

1.33 [0.93, 1.87]
1.35 [0.97, 1.88]

1.32 [0.93, 1.87]
1.35 [0.97, 1.88]

1.41 [1.09, 1.82] **

1.42 [1.10, 1.83] **

1.42 [1.10, 1.84] **

1.42 [1.10, 1.83] **

1.03 [0.79, 1.34]

1.03 [0.79, 1.34]

1.03 [0.79, 1.34]

1.23 [0.89, 1.70]

1.23 [0.89, 1.70]

1.23 [0.89, 1.70]

No
Any tobacco/alcohol use disorder
Yes
1.03 [0.79, 1.34]
No
Any drug use disorder
Yes
1.23 [0.89, 1.70]
No
Obesity
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Yes
No

1.08 [0.81, 1.44]

1.08 [0.80, 1.44]

1.08 [0.80, 1.44]

1.08 [0.80, 1.44]

State level: Environmental factors
Poverty

‡‡

-

High
Low
Rurality ‡‡

0.87 [0.32, 2.34]

0.68 [0.27, 1.68]

0.62 [0.27, 1.43]

High
Low
Mental health provider shortage ‡‡

2.43 [0.90, 6.54]

1.03 [0.36, 2.91]

0.94 [0.35, 2.47]

-

-

5.38 [1.87, 15.50] **

4.65 [1.72, 12.60] **

2nd quartile

-

-

-

2.62 [1.09, 6.28] *

3rd quartile
4th quartile
1st quartile

-

-

-

2.53 [0.98, 6.55]
1.65 [0.55, 4.95]

High
Low
TMH capacity §§

Random-effect parameters
¶¶

***

LR test
503.60
451.45 ***
315.86 ***
186.67 ***
Residual variance
2.51 (0.75)
2.28 (0.68)
1.74 (0.54)
1.38 (0.47)
†††
VPC
0.43
0.41
0.35
0.30
Note: AOR (95%CI): adjusted odds ratio and associated 95% confidence interval estimated from multilevel
logistic regressions.
HMO: health maintenance organization. Non-HMO include plans from preferred provider organizations, point of
services, fee-for-service, and others.
MA: Medicare Advantage. Non-MA plans were other commercial insurances.
†
all patient-level factors were measured in the six-month period before index dates based on de-identified claims
of Optum Clinformatics ® DataMart. The first TMH use date was used as index date for users and a pseudo-index
date was randomly selected from all mental health service dates among non-users.
‡
average monthly out-of-pocket (OOP) expenditures were categorized as zero, low, and high. Low/high OOP
expenditures were defined as the lower and upper 50 th percentiles.
§
the severity of mental health conditions was measured with a algorithm developed by researchers from the
Healthcare Cost and Utilization Project based on diagnostic codes from claims.
¶
chronic conditions examined included arthritis, asthma, coronary artery disease, cardiac arrhythmias, congestive
heart failure, chronic kidney disease, chronic obstructive pulmonary disease, dementia and related disorders,
diabetes, hypertension, hyperlipidemia, osteoporosis, stroke.
††
polypharmacy was defined as having more than five medications from different therapeutic classes in the 90
days before index date.
‡‡
poverty, rurality, and mental health provider shortage were measured as average percentages of counties under
qualified for each condition from 2010-2016 based on data from the 2016-2017 Area Health Resources File.
Low/high levels were defined as the lower and upper 50th percentiles.
§§
TMH capacity was measured as average percentages of mental health facilities with telemedicine from 20102016 based on data from the 2010-2016 National Mental Health Services Survey.
¶¶
Log-likelihood test was used to assess the significance of multilevel models against single-level models.
†††
VPCs were calculated with the formula: level-2 residual variance / (level-1 residual variance + level-2 residual
variance), where level-1 residual variance for logistic model = 3.29.
*
, p < 0.05; **, p < 0.01; ***, p < 0.001.

56

Table 3.3 Results of multilevel logistic regressions on Telemental health use (yes/no) among
Medicare Advantage enrollees with mental health conditions (MHC) who lived in underserved
states.
AOR (95%CI)
1.37 [1.28, 1.47] ***

Year of TMH use
Patient-level: Predisposing factors †
Age
18 – 64 years
65 years or older

1.99 [1.52, 2.60] ***

Sex
Female
Male

1.19 [0.93, 1.52]
Patient-level: Health insurance characteristics †

Plan type
Health Maintenance Organization (HMO)
Non-HMO
Monthly out-of-pocket expenditures
Low (1st & 2nd quartile)
High (3rd & 4th quartile)
Zero
Patient-level: Need factors †
Any severe MHC
Yes
No
Any in-person mental health specialist visit
Yes
No
Number of physical chronic conditions ‡
1-2
3 or more
None
Polypharmacy §
Yes
No
Any tobacco/alcohol use disorder
Yes
No
Any drug use disorder
Yes
No
Obesity
Yes
No
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0.84 [0.62, 1.13]

1.39 [1.02, 1.89] *
1.57 [1.15, 2.13] **

1.83 [1.36, 2.46] ***

9.86 [7.40, 13.14] ***

1.24 [0.81, 1.90]
1.25 [0.86, 1.82]

1.19 [0.90, 1.58]

0.98 [0.73, 1.33]

1.18 [0.81, 1.72]

1.01 [0.73, 1.41]

State level: Environmental factors
Poverty

¶

High (3rd & 4th quartile)
Low (1st & 2nd quartile)

0.50 [0.24, 1.05]

Rurality ¶
High (3rd & 4th quartile)
0.80 [0.34, 1.84]
Low (1st & 2nd quartile)
Mental health provider shortage ¶
High (3rd & 4th quartile)
4.29 [1.79, 10.29] **
Low (1st & 2nd quartile)
TMH capacity ††
High (3rd & 4th quartile)
1.53 [0.88, 2.65]
st
nd
Low (1 & 2 quartile)
Random-effect parameters
Likelihood Ratio test vs. logistic model
76.94 ***
Residual variance
1.00 (0.38)
‡‡
Variance Partition Coefficients (VPCs)
0.23
Note: AOR (95%CI): adjusted odds ratio and associated 95% confidence interval estimated
from multilevel logistic regressions. Underserved states were defined as states with high
percentages of rural counties or counties with shortage of healthcare providers.
†
all patient-level factors were measured in the six-month period before first TMH use
based on de-identified claims of Optum Clinformatics ® DataMart. The first TMH use date
was used as index date for users and a pseudo-index date was randomly selected from all
mental health service dates among non-users.
‡
chronic conditions examined included arthritis, asthma, coronary artery disease, cardiac
arrhythmias, congestive heart failure, chronic kidney disease, chronic obstructive
pulmonary disease, dementia and related disorders, diabetes, hypertension, hyperlipidemia,
osteoporosis, stroke.
§
polypharmacy was defined as having more than five medications from different
therapeutic classes in the 90 days before index date.
¶
poverty, rurality, and mental health provider shortage were measured as average
percentages of counties under qualified for each condition from 2010-2016 based on data
from the 2016-2017 Area Health Resources File.
††
TMH capacity was measured as average percentages of mental health facilities with
telemedicine from 2010-2016 based on data from the 2010-2016 National Mental Health
Services Survey.
‡‡
VPCs were calculated with the formula: level-2 residual variance / (level-1 residual
variance + level-2 residual variance), where level-1 residual variance for logistic model =
3.29.
*
, p < 0.05; **, p < 0.01; ***, p < 0.001.
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Figure 3.1 Aim 2 Cohort identification process.
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Figure 3.2 Distribution of selected mental health (MH) services delivered via Telemental health
(TMH)/in-person.
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CHAPTER 4
4 The Impact of Telemental Health (TMH) Use on Healthcare Costs Among Commercially
Insured Adults with Mental Health Conditions
4.1 Abstract
Objective: To determine the impact of TMH use on total healthcare costs and mental health
(MH)-related costs paid by a third party among adults with mental health conditions (MHC).
Method: This study employed a pre-post design with a non-equivalent control group. The cohort
comprised adults with MHCs identified using diagnosis codes from de-identified claims data of
the Optum Clinformatics ® DataMart (01/01/2010 - 06/30/2017). We identified MH service users
and TMH users (N = 348) based on procedure codes. Non-users (N = 238,595) were defined as
those who only used in-person MH services. A Difference-in-Differences (DID) analysis was
performed within a multivariable two-part model (TPM) framework to examine the impact of
TMH use on adjusted standardized costs (2018 US $) of all healthcare services and MH services.
Patient-level and state-level factors were adjusted in TPM. Results: TMH use was associated
with significantly higher MH-related costs [Marginal effect = $461.3, 95% confidence interval:
$142.4 – $780.2] and an excess of $370 increase in MH-related costs at follow-up as compared
to baseline. However, TMH use was not associated with an increase in total third-party
healthcare costs nor with changes in total costs from baseline to follow-up. Conclusions: Despite
having a higher likelihood of MH services use and MH-related costs, TMH users did not have
higher total costs as compared to adults using only in-person MH services. Our findings suggest
that TMH can increase access to MH care without increasing total healthcare costs among adults
with MHC.
4.2 Highlights
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•

Existing clinical trials have demonstrated that MH services delivered via TMH are
comparable to those delivered in-person for assessing and treating various MHCs.
However, there is a concern that TMH may increase healthcare utilization and costs.

•

This study is the first to examine the impact of TMH use on third-party healthcare costs
and mental health (MH)-related costs by comparing the changes in costs between TMH
users and in-person MH service users (i.e., without TMH use) among adults with MHCs
seeking care in real-world clinical settings.

•

The study results suggested that TMH use was associated with an excess of $370 in MHrelated costs from baseline to follow-up. However, TMH users did not differ significantly
from non-users in average total healthcare costs. Future studies are warranted to
determine if this apparent cost-offset is due to improvements in MH and physical health
outcomes or to other factors.

4.3 Introduction
Mental health conditions (MHCs) are the most expensive conditions among ten
conditions with fast spending growth (i.e., heart conditions, trauma, cancer) in the United States,
with an estimated excess cost of $38 billion in direct healthcare expenses in 2013.102 The high
MHC prevalence coupled with continued undertreatment of MHC have contributed significantly
to this high economic burden. 8,80,103 Telemental health (TMH) has emerged as an alternative
care delivery approach to meet the growing demand of MH care and shortages of MH
providers.126 TMH is the use of remote technologies such as video-conferencing systems to
deliver MH care.106 Clinical trials have shown that TMH is well accepted 107,127,128 and has
comparable efficacy in the evaluation and treatment of MHC patients across a broad range of
demographic groups.51-54,129
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Although the comparative efficacy of TMH in delivering MH care relative to in-person
care is well-documented in clinical trials,51-54,129 studies on outcomes of TMH use among adults
with MHCs in real-world settings are sparse, limited primarily to those using data from the
Veterans Health Administration. For instance, a study examining outcomes of 98,609 veterans
receiving TMH services reported a 25% reduction in psychiatric admissions and hospital stays
after initiating TMH over four years.60 However, the study did not compare the changes in
healthcare utilization and costs between individuals with TMH use and those with only in-person
MH services use,60 limiting interpretation of findings.
To establish the true value of TMH services, studies comparing healthcare utilization and
costs among MHC patients receiving TMH and in-person MH services are warranted. In
response to the rising healthcare costs, the Institute of Health Improvement developed the “Triple
Aim” to define high-value care as care that can improve population health and individual care
experience with reduced per-capita costs.61 In alignment with the “Triple Aim,” the National
Quality Forum (NQF) and the American Telemedicine Association use healthcare costs as one of
the key measurements in their newly developed telehealth value framework. 62 However,
previous studies have primarily focused on indirect medical costs such as time and expenses
related to travel. 130-132 No study has compared the direct healthcare costs of individuals with
MHC who used TMH services with that of individuals with MHC who used only in-person MH
services. Understanding the relative utilization and direct care costs will help inform and guide
the decisions of healthcare payers regarding the expansion of TMH coverage. 67
Therefore, the primary objective of this study was to determine the impact of TMH use
on total healthcare costs and mental health (MH)-related costs among adults with mental health
conditions (MHC) using data from a large commercial insurer.
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4.4 Methods
Data source
Data (January 2010 through June 2017) were derived from Optum Clinformatics ®
DataMart (Eden Prairie, MN, USA), a large commercial health plan in the US Data included deidentified medical claims of physician, hospital, and prescription drug services as well as
enrollment information for covered individuals from all 50 states and the District of Columbia.108
We linked claims data with that from the 2016-2017 Area Health Resources File (AHRF) 109 and
the 2010-2016 National Mental Health Services Survey (N-MHSS) 78 using state identifiers. The
linkage was conducted to obtain state-level information on poverty, rurality, and MH provider
shortage from the AHRF, as well as the TMH capacity from N-MHSS files.
Study design
We used a pre-post study design with a non-equivalent control group. The pre- (baseline)
and post- (follow up) periods each consisted of six months. For TMH users, the first TMH
service date after 12 months of MHC diagnosis was used as the index date. For those who used
only in-person MH services (i.e., non-users), a pseudo-index date was randomly selected from all
MH service dates between 2010 and 2016 to allow a six-month follow-up. Standardized costs
were assessed for both six months before (i.e., baseline) and six months after (i.e., follow-up) the
index/pseudo-index dates.
Study cohort
The study cohort comprised adults (> 18 years old at baseline) who were diagnosed with
any MHC between 2010 and 2016, who had at least one MH service encounter 12months after
the MHC diagnosis, and who were continuously enrolled in any health plan during the baseline
and follow-up periods. We identified adults with MHC based on the primary and secondary
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diagnosis codes [the International Classification of Diseases, Ninth Revision (ICD-9) codes: 291292; 295-316; ICD-10: F10-F99] in inpatient and outpatient medical claims.42 Adults with MCH
were defined as those with an MCH diagnosis from at least two outpatient visits or one inpatient
admission. 42 MH service encounters were identified with procedure codes (Appendix 7.1) or
primary/secondary diagnostic codes of any MHC.42 Data on adults with MHC for each year
(2010-16) were combined to form the study cohort. The cohort identification process is
illustrated in Figure 4.1. The final analytic cohort included 238,943 unique adults with MHC.
Measures
Outcomes
Standardized total healthcare costs included total insurer-allowed payments for inpatient
stays, facility outpatient visits, professional services, and prescription drugs during the period
assessed. To account for differences in allowed payments across health plans and provider
contracts, standardized prices were used to represent allowed payments. Standardized prices for
medical services and prescription drugs were estimated using algorithms developed by the
Optum researchers, accounting for the type and quantity of services as well as the relative
resource costs involved in providing the service. All the costs were normalized to 2018 US
dollars using the standard prices and cost factors provided by Optum Clinformatics ® DataMart.
MH–related costs were estimated by summing up all allowed payments from the insurer
for MH services using standard prices and cost factors. MH services were identified by
procedure or primary/secondary diagnostic codes as described above (study cohort part).
Key independent variable: TMH use versus (vs.) No TMH use
We defined comparison groups based on TMH use (yes/no), identified from MH service
claims using the relevant Healthcare Common Procedure Coding System (HCPCS)/Current
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Procedural Terminology (CPT) codes (“0188T”, “0189T”, “G0406 - 0408”, “G0425 - 0427”,
“G0459”) and/or modifiers (“GT”, “GQ”, “95”).42,49 These codes were listed on the policy
document of the insurer and have been used in a previous study of TMH among Medicare
beneficiaries.42,49 The TMH user group included adults with MHC who had any record of TMH
use; non-user group included those who used only in-person MH services.
Other independent variables
We selected other independent variables based on the adapted Andersen’s Behavioral
Model of Health Services Use.74 The model posits that individual healthcare utilization is a
function of multiple factors, including 1) predisposing factors (age, sex); 2) enabling factors
[TMH use (yes/no), type of insurance (Medicare Advantage/others), type of health plan (Health
Maintenance Organization/others); 3) need factors [severe MHC diagnosis (yes/no), mental
health specialist visits (yes/no); the number of physical chronic conditions (none/one or
two/three or more); or the presence of polypharmacy (use of > 5 drug classes in a 90-day period
111

), obesity, and/or any substance (i.e., alcohol, tobacco, drug) use disorders (SUD)]; and 4)

environmental factors (the percentage of: counties under poverty, rural counties, counties with
MH provider shortage, and MH facilities with TMH adoption by state). We also adjusted for the
year of TMH use to account for the effect of time. Time from MHC diagnoses to index/pseudoindex dates (136

104 days) was also included in the multivariable analyses.

All need factors were identified from inpatient and outpatient claims using ICD9/ICD10
diagnostic codes. An algorithm developed by researchers of the Healthcare Cost and Utilization
Project was used to define the severity of MHCs using ICD9/10 diagnostic codes.112 The severity
classes derived from this algorithm were strong predictors of hospitalizations after an Emergency
department visit.112 The number of chronic physical conditions [range 0-13, based on a list
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developed by the Multiple Chronic Conditions (MCC) working group 113] were also ascertained
using ICD9/ICD10 codes from claims data. All patient-level factors were measured at the
baseline and follow-up period. Environmental factors, measured at the state level, were
ascertained using data from the AHRF.
Statistical analyses
Chi-square tests and independent t-tests were conducted to compare the characteristics of
TMH users and non-users at baseline and follow-up, respectively. Standard linear regression is
usually not appropriate for modeling costs due to certain common characteristics of cost data,
including zero mass, non-negative values, and positive skewness.133 Therefore, we used a mixed
distributions approach to model costs. Specifically, we used two-part models (TPM), in which
the probability of non-zero costs (yes/no) was modeled with logistic regressions, and the
magnitude of costs was modeled within Generalized Linear models (GLMs) using gamma
distributions and log-link functions. 133 The marginal effect (ME) and associated 95% confidence
interval (95%CI) were used to represent the parameter estimate. As need factors were derived
from claims of service encounters, we adjusted for need factors in GLM but not in the logistic
regression analyses. We adjusted for all other independent variables in both parts of TPM; these
variables include the year of TMH use, time from MHC diagnosis to index/pseudo-index dates,
and predisposing-, enabling-, and environmental factors. A Difference-in-Differences (DID)
estimate was included in the TPMs to estimate the excess change in both total third-party
healthcare costs and MH-related costs due to TMH use. The DID estimate is an interaction term
of TMH use (yes vs. no) and time (follow-up vs. baseline), representing the effect of using TMH
on cost changes from baseline to follow-up.134 For all analyses in this study, a p-value less than
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0.05 was considered statistically significant. All data management and analyses were performed
with SAS 9.4 (SAS Institute Inc., Cary, NC) and Stata 14 (StataCorp LLC, College Station, TX).
4.5 Results
Sample description
A total of 238,943 adults with MHC were identified. The most prevalent MHC was
anxiety disorder (42.4%). About one-third of the study sample had serious MHCs such as
schizophrenia (1.4%), bipolar disorder (7.6%), and major depressive disorder (24.7%). The
sample was predominantly female (61.5%), with a mean age of 48.5 years (SD = 18.3).
Overall, only 15 in 10,000 adults with MHCs used TMH (Table 1). At both baseline and
follow-up, TMH users differed significantly from non-users in age and in all enabling-, need-,
and environmental factors and non-users (Table 1). For example, at baseline, a higher percentage
of TMH users had received a serious MHC diagnosis (75.6% vs. 32.2%, p < 0.001) and had
visited a mental health specialist (51.2% vs. 19.2%, p < 0.001) as compared to non-users.
Furthermore, a greater percentage of TMH users than non-users had a record of polypharmacy
(54.3% vs. 27.7%, p < 0.001) and had been diagnosed with at least two comorbid chronic
conditions (61.2% vs. 32.7%, p < 0.001). The distribution of all patient-level factors within each
group was similar at baseline and follow-up (Table 1).
Unadjusted and adjusted MH-related costs
As illustrated in Table 2, “within” group differences in MH-related costs varied between
TMH users and non-users. While a similar percentage of TMH users received MH services at
baseline and follow-up (29.9% vs. 33.3%, p = 0.548), the percentage of non-users receiving MH
services declined significantly (from 13.9% to 8.3%, p < 0.001) from the baseline to the followup period. Similarly, average MH-related costs for TMH users did not change significantly from
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baseline to follow-up ($9,703.7 vs. $11,009.1, p = 0.643). In contrast, the average MH-related
costs for non-users increased significantly during this period (from $7,417.3 to $8,894.3, p <
0.001).
Between group comparisons using DID analysis indicated that TMH users were over
twice as likely than non-users to utilize MH services after adjustment for other factors (AOR:
2.06, 95%CI: 1.62 – 2.63). Based on the marginal effect estimate, TMH use was also associated
with $461.3 higher MH-related costs. Furthermore, after adjusting for other factors, TMH user
had increased MH-related costs at follow-up as compared to baseline, and these increased costs
were $369.6 higher than those among non-users, after adjusting for other factors. (Table 3).
Other factors associated with higher MH-related costs included MA enrollment, all need
factors such as having polypharmacy, any SUD, and multiple chronic physical conditions, and
living in states with high levels of poverty (Appendix 7.2 supplemental table).
Unadjusted and adjusted total healthcare costs
Table 2 presents the average unadjusted total costs and MH-related costs among TMH
users and non-users at baseline and follow-up. When comparing follow-up utilization and costs
to those at baseline, TMH users had similar percentages of individuals with zero costs (5.7% vs.
6.0%) and average total healthcare costs ($12,960.1 vs. $13,336.6) at baseline and follow-up.
However, among non-users, a significantly higher percentage of individuals had zero costs at
follow-up than at baseline (7.9% vs. 7.1%, p < 0.001), with a corresponding decrease in average
total healthcare costs ($6,115.6 at follow-up vs. $6,642.3 at baseline, p < 0.001).
Group difference in differences from baseline to follow-up were examined with
multivariable DID analysis within a TPM framework. Results from DID analysis indicated that
TMH use (ME = -$253.9, 95%CI: -$1,601.5 - $1,093.7) was not associated with total healthcare
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costs. Furthermore, TMH use (ME of DID estimate = $554.3, 95% CI: -$1,005.2 – $2,113.8) had
no significant impact on the change in healthcare costs from baseline to follow-up (Table 3).
Other factors contributing to higher total third-party costs were similar to those for higher MHrelated costs (Appendix 7.2 supplemental table).
4.6 Discussion
Our study is the first to compare direct total third-party healthcare costs and MH-related
costs among adults with MHCs who used TMH services and those used only in-person MH
services (i.e., non-users). It has been reported that payers may be less likely to adopt TMH due
to the fear of higher utilization and costs associated with TMH 135. Our findings suggest that
TMH use did not have an impact on total healthcare costs. However, TMH use was associated
with a greater likelihood of using MH services, suggesting that TMH may have increased access
to MH services for adults with MHC. Although our study did not have information on wait time,
published studies suggest that TMH may contribute to increased utilization by reducing the wait
time for MH services. For example, in a study evaluating a Telemental health clinic, the number
of days to the first service was 42% shorter for services delivered via TMH than in-person
services (19.1 vs. 33.1, p < 0.001), and the wait time for medication management via TMH was
43.2% of that for in-person services 136.
It is worth noting that, in our study, TMH was associated with increased MH-related
costs but not total healthcare costs, suggesting that reduced use of non-MH services may offset
the incremental costs from using MH services. Although we were not able to analyze the source
of this cost-offset (e.g., reduced inpatient use, reduced emergency room visits) due to small
sample sizes, it is plausible that TMH may have positive spill-over effects on physical health,
resulting in decreased use of non-MH services. Such “cost-offset effect” following MH treatment
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has been reported in other clinical populations, including adults with co-existing depression and
diabetes 137. As a key priority of the patient-centered medical home model (PCMH) is to
integrate mental and physical health, TMH may offer unique opportunities to achieve such
integration 138. Future study is needed to explore how to incorporate TMH in the PCMH model.
The increased costs of MH services might also be offset by TMH-facilitated medication
management. Polypharmacy was prevalent among adults with MHC in our study, characterizing
27.8% of adults with MHC overall and 56.6% of those with TMH use (Table 1). We found that
the presence of polypharmacy was significantly associated with both higher healthcare costs and
MH-related costs (Appendix 7.2 supplemental table). Without proper management,
polypharmacy has been shown to increase healthcare costs due to elevated risks of adverse drug
reactions and drug-drug interactions 139. Medication management is one of the most commonly
used TMH services 140. Studies have demonstrated the efficacy of TMH in improving medication
adherence and associated clinical outcomes 141,142. Furthermore, TMH allows for frequent short
visits if necessary, such as those for reviewing medications, a feature that is especially valuable
for patients for whom travel is difficult due to distance, weather, poor health, or other challenges
(i.e., obesity).
In brief, findings of our study suggest TMH may expand access to MH services without
increasing total healthcare costs. Access to SUD treatments is even more limited than access to
MH services, with only one in ten individuals with SUD received treatments 143. As SUD and
MH treatments share common barriers (e.g., provider shortage, stigma), much attention has been
focused on the potential for using telehealth to increase access to SUD care 97,144. Having any
substance use disorders (SUD) was a significant contributor to overall healthcare ($3,981.2 $4,798.9) costs and MH-related costs ($201.3-$382.9) in our study (Appendix 7.2 supplemental
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Table). Cost-saving might be achieved in the future by employing telehealth for delivery of SUD
care. A recent study of claims data had reported a very low rate of use (0.62 visits/1,000 patients)
of telehealth in treating SUD in real-world practice 110. The low usage was partially due to
regulatory and reimbursement barriers in prescribing SUD treatments via telehealth approach 110.
Given that SUD and MHC often co-occur, expanding telehealth coverage for SUD may also help
reduce healthcare costs among adults with MHCs.
This study has several strengths, including the population-based design and comparison
of TMH vs in person mental health care use in a real-world setting. We standardized prices of
medical services and prescriptions to estimate healthcare costs to facilitate comparison across
patients with different health plans and provider contracts. Our study cohort comprised a
geographically diverse sample of adults with different MHCs, increasing generalizability of the
study findings. Furthermore, we employed a pre-post DID study design, which allowed us to
account for certain unobserved factors (e.g., disease severity) that may affect healthcare costs 134.
Several limitations of the study should also be noted. First, our study estimated only
direct healthcare costs and our study population was restricted to adults enrolled in a single
private insurance plan. Indirect healthcare costs such as those related to travel of patients, their
family members, and providers were not considered. Given that multiple studies have
demonstrated that TMH can reduce indirect healthcare costs due to lost productivity (e.g., time
off from work) and transportation expenses 54,64,145, indirect MH costs are likely to be
comparable or lower for MHC patients who used TMH as compared to those used in-person MH
services. Second, we only estimated costs for MH services. Costs of prescription medications
used to treat MHCs were not included because some of these medications (e.g., antidepressants)
are often used to treat physical conditions such as pain and insomnia 146. Third, due to the limited
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sample size, we did not conduct subgroup analyses to compare the costs of specific MH services
delivered via TMH vs. in-person. Furthermore, as this study compared short-term (i.e., six
months) healthcare costs between TMH users and non-users. The long-term impact of TMH use
on healthcare costs among adults with MHCs thus warrants further examination. Finally,
although our study cohort was drawn from enrollees in one of the largest commercial plans in the
country, our results may not be generalizable to MHC patients insured by other commercial
plans.
4.7 Conclusion
This is the first study to examine the association between TMH use and direct healthcare
costs over time from a private payer's perspective. TMH use was associated with an increased
utilization of MH services and a corresponding excess in MH-related costs due to. However,
TMH use did significantly affect total third-party healthcare costs. Future studies should examine
the sources of this apparent “cost-offset” and explore whether TMH use can lead to cost-savings
over a longer period.
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Table 4.1 Characteristics of adults with mental health conditions (MHCs) who used Telemental
health (TMH) and those used in-person mental health (MH) services at baseline and follow-up,
Optum Clinformatics ® DataMart, 2010-2017
Baseline
TMH users

Total
Age [mean (SD)],
years
Sex
Female
Male
Medicare Advantage
Yes
No
Plan type
HMO
Non-HMO

N
348

Col. %
100.00

58.18 (15.51)

Non-users

TMH users

N
Col. % Sig. N
238,595
100.00
348
a
Predisposing factors
48.42 (18.33)

***

207
141

59.48
40.52

146,692
61.48
91,903
38.52
Enabling factors a

296
52

85.06
14.94

67,545
171,050

Col. %
100.00

58.23 (9.78)

Non-users
N
238,595

Col. %
100.00

48.46 (18.34)

207
141

59.48
40.52

146,692
91,903

61.48
38.52

296
52

85.06
14.94

67,537
171,058

28.31
71.69

***
28.31
71.69

153
195

43.97
56.03

52,808
185,787

70
65
213

20.11
18.68
61.21

Yes
189
54.31
No
159
45.69
Any tobacco/alcohol use disorder
Yes
77
22.13
No
271
77.87
Any drug use
disorder
Yes
47
13.51
No
301
86.49
Obesity

112,805
47,726
78,064

22.13
77.87
Need factors a

153
195

43.97
56.03

52,759
185,836

22.11
77.89

253
95

72.70
27.30

55,149
183,446

23.11
76.89

207
141

59.48
40.52

42,480
196,115

17.80
82.20

***

***
19.18
80.82
***
47.28
20.00
32.72

***
78
53
217

22.41
15.23
62.36

124,098
42,051
72,446

52.01
17.62
30.36

***
66,130
172,465

27.72
72.28

40,161
198,434

16.83
83.17

***
197
151

56.61
43.39

62,898
175,697

26.36
73.64

73
275

20.98
79.02

24,202
214,393

10.14
89.86

**

**

***
13,677
224,918

***

***

***
32.20
67.80

Sig.

***

***

Any severe mental health diagnosis
Yes
263
75.57
76,835
No
85
24.43
161,760
Any mental health specialist visit
Yes
178
51.15
45,772
No
170
48.85
192,823
Number of physical chronic conditions b
Zero
One
Two or more
Polypharmacy c

Follow-up

5.73
94.27

42
306
***

74

***
12.07
87.93

9,608
228,987

4.03
95.97
***

Yes
No

57
291

16.38
83.62

19,235
8.06
47
219,360
91.94
301
Environmental factors
**

13.51
86.49

16,571
222,024

6.95
93.05

165

47.41

92,997

38.93

165

47.41

92,997

38.93

183

52.59

145,869

61.07

183

52.59

145,869

61.07

Poverty d
Low (1st & 2nd
Quartile)
High (3rd & 4th
Quartile)
Rurality d

**

***

Low (1st & 2nd
174
50.00
Quartile)
High (3rd & 4th
174
50.00
Quartile)
Mental health provider shortage d

***

149,879

62.75

174

50.00

149,879

62.75

88,987

37.25

174

50.00

88,987

37.25

***

***

Low (1st & 2nd
Quartile)
High (3rd & 4th
Quartile)
TMH capacity e

101

29.02

130,580

54.67

101

29.02

130,580

54.67

247

70.98

108,286

45.33

247

70.98

108,286

45.33

1st Quartile
2nd Quartile
3rd Quartile
4th Quartile)
Lagging time
[mean (SD)], daysf

22
86
145
95

6.32
24.71
41.67
27.30

62,555
72,528
48,624
55,159

26.19
30.36
20.36
23.09

22
86
145
95

6.32
24.71
41.67
27.30

62,555
72,528
48,624
55,159

26.19
30.36
20.36
23.09

***

179.0 (105.0)

136.2 (104.4)

***

***

179.0 (105.0)

136.2 (104.4)

***

Note: TMH users were defined as adults with MHC used any TMH services; non-users were defined as adults with
MHC who only used in-person MH services.
Col.%: Column%; SD: standard deviation; Sig.: significance level;
HMO: health maintenance organization;
a
all patient-level factors were measured in the six-month period before and after index date based on de-identified
claims of Optum Clinformatics ® DataMart. The first TMH use date was used as index date for users and a pseudoindex date was randomly selected from all mental health service dates among non-users.
b
chronic conditions examined included arthritis, asthma, coronary artery disease, cardiac arrhythmias, congestive
heart failure, chronic kidney disease, chronic obstructive pulmonary disease, dementia and related disorders,
diabetes, hypertension, hyperlipidemia, osteoporosis, stroke.
c
polypharmacy was defined as having five or more medications from different therapeutic classes in the 90 days
before index date.
d
poverty, rurality, and mental health provider shortage were measured as average percentages of counties under
qualified for each condition from 2010-2016 based on data from the 2016-2017 Area Health Resources File.
e
TMH capacity was measured as average percentages of mental health facilities with telemedicine from 2010-2016
based on data from the 2010-2016 National Mental Health Services Survey.
f
lagging time reflects the number of days between first observed MHC diagnosis in claims to index date/pseudoindex date.
**
, p < 0.01; ***, p < 0.001.
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Table 4.2 Unadjusted mean and Standard Deviation (SD) of baseline and follow-up costs (2018 US
$) of adults with mental health conditions (MHC) who used Telemental health services and those
used in-person mental health (MH) services, Optum Clinformatics ® DataMart, 2010-2017
All adults with MHC
TMH users
Baseline

Non-users

Follow-up

N

Mean
(SD)

N

Mean
(SD)

Total a

348

12,960.56
(24,260.72)

348

13,336.58
(26,420.70)

MHrelated b

348

2,927.83
(10.980.45)

348

3,669.71
(11,899.49)

Sig.

Baseline

Follow-up

Sig.

N

Mean
(SD)

N

Mean
(SD)

ns

238,595

6,642.34
(23,519.44)

238,595

6,115.61
(21,312.88)

***

ns

238,595

1,035.34
(6,775.67)

238,595

735.94
(6,091.44)

***

Adults with MHC with specific service use
TMH users
Baseline
N

Mean
(SD)

Non-users

Follow-up
N
(%)

Sig.

Mean
(SD)

Baseline

Follow-up

N (%)

Mean
(SD)

N (%)

Mean
(SD)

Sig.

Total a

327

13792.89
(24,798.83)

328

14149.79
(27,003.81)

ns

221,638

7,150.53
(23946.90)

219,822

6,637.88
(22,126.10)

***

MHrelated b

105

9,703.66
(18,327.71)

116

11,009.12
(18,594.44)

ns

33,304

7,417.31
(16,780.17)

19,742

8,894.29
(19,388.17)

***

Note: All outcomes were measured based on de-identified claims of Optum Clinformatics ® DataMart. All the
costs were standardized to 2018 US dollar. Baseline and follow-up period were defined as the six-month period
before and after index/pseudo-index date, respectively. The first TMH use date was used as index date for users
and a pseudo-index date was randomly selected from all mental health service dates among non-users.
TMH users were defined as adults with MHC used any TMH services; non-users were defined as adults with MHC
who only used in-person MH services.
a
total healthcare costs included the standard costs for all healthcare services paid by payers, including those for
outpatient visits, inpatient stays, and prescription medications.
b
MH-related utilizations and costs were identified based on primary/secondary diagnoses of any MHC.
c
%MH costs were calculated as the average percentage of MH-related costs among the total healthcare costs for
individuals with positive MH-related costs.
ns, p > 0.05; ***, p < 0.001.
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Table 4.3 Parameter estimates of Telemental health use (TMH) from difference-in-differences (DID)
analyses for total healthcare costs and total costs for mental health services (MHS) at follow-up among
adults with mental health conditions (MHC), Optum Clinformatics ® DataMart, 2010-2017
Total healthcare costs a
Logistic
AOR (95%CI)
TMH use
Yes vs. No
Time
Follow-up vs. baseline
DID c

GLM
Adjusted Beta (SE)

Marginal effect
Mean (95%CI), $

1.06 (0.68, 1.66)

-0.043 (0.104)

-253.9 (-1,601.5, 1,093.7)

0.89 (0.88, 0.91) ***

0.023 (0.009) **

-197.1 (-307.0, -87.2) ***

1.18 (0.70, 2.00)

0.074 (0.121)

554.3 (-1,005.2, 2,113.8)

Total MH-related costs
Logistic
AOR (95%CI)

b

GLM
Adjusted Beta (SE)

Marginal effect
Mean (95%CI), $

TMH use
Yes vs. No

1.84 (1.44, 2.34)

0.130 (0.203)

461.3 (142.4, 780.2) ***

Time
Follow-up vs. baseline

0.56 (0.55, 0.57) ***

0.108 (0.016) ***

-269.9 (-294.3, -245.5) ***

DID c

2.06 (1.62, 2.63) ***

-0.097 (0.232)

369.6 (13.9, 725.4) *

Note: All outcomes were measured based on de-identified claims of Optum Clinformatics ® DataMart. All the costs were
standardized to 2018 US dollar. Baseline and follow-up period were defined as the six-month period before and after
index/pseudo-index date, respectively. The first TMH use date was used as index date for users and a pseudo-index date
was randomly selected from all mental health service dates among non-users.
AOR (95%CI): adjusted odds ratio and associated 95% confidence interval were estimated from logistic regressions on the
probability of non-zero costs.
SE: standard error was estimated from two-part models, where the first part estimated the probabilities of having non-zero
costs in a logistic regression and the second part estimated positive costs in a generalized linear model (GLM) with log-link
functions and gamma distributions.
a
Total healthcare costs included the standard costs for all healthcare services paid by payers, including those for outpatient
visits, inpatient stays, and prescription medications.
b
Total costs for mental health services were identified based on primary/secondary diagnoses of any MHC from outpatient
and inpatient claims.
c
DID is the interaction term of TMH use and Time, representing the impact of TMH use on the changes of outcomes from
baseline to follow-up.
**
, p < 0.01; ***, p < 0.001.
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Figure 4.1 Aim 3 Cohort identification process.
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CHAPTER 5
5 Summary and Conclusion
5.1 Summary
Mental health was among the first clinical areas where telehealth technologies were
applied to improve access to care.147 Understanding the adoption of TMH among mental health
facilities is a critical step in the broad implementation of TMH in the delivery system of mental
healthcare. Examining facility- and state-level factors that may influence facility-level decisions
to invest in TMH can inform federal and state-level policy initiatives and aid in improving the
adoption of TMH by facilities. As the use of TMH is determined by not only "supply" but also
"demand," it is also important to understand TMH use among adults with MHC. Examining
TMH use among patients with MHC can establish benchmarks for demand in TMH and suggest
future directions for expanding TMH services. In alignment with the “Triple Aim,” the National
Quality Forum (NQF) and the American Telemedicine Association use healthcare costs as one of
the critical measurements in their newly developed telehealth value framework.62 Therefore,
evaluating how TMH use influences healthcare utilization and costs among adults with MHC can
establish the value of TMH services, which will, in turn, help inform and guide healthcare
payers’ decisions of expanding TMH coverage.67
However, a comprehensive examination of the adoption and impact of TMH in the realworld clinical practice setting is lacking. Given that commercial insurances plays an important
role in paying for mental health services and telehealth services,38,48 it is imperative to examine
TMH use and the impact of TMH use on healthcare costs among commercially insured adults
with MHC. Therefore, this dissertation pursued three related aims: 1) to estimate TMH adoption
and examine factors associated with TMH adoption among mental health facilities; 2) to
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characterize TMH use and identify factors associated with TMH use among commercially
insured adults with MHC; and 3) to evaluate how TMH use influence healthcare costs. To
comprehensively present the state of art of TMH in the current mental health delivery system, the
study used diverse data sources. These data sources included: the National Mental Health
Services Survey (N-MHSS) for years 2011-2016; a geographically diverse claims database for
commercially insured adults for years 2010-2017; the latest Area Health Resources File (20162017); and national reports of telehealth policies.
TMH Adoption among Mental Health Facilities
We found that about one in four mental health facilities in the US incorporated TMH as a
treatment approach by 2016. The adoption of TMH by a mental health facility could be
influenced by multiple facility- and state-level factors. TMH adoption was more likely among
facilities that were part of the VHA system, included outpatient settings, had public ownership,
had comprehensive MH treatments or Quality Improvement practices, had Information
Technology (IT) capacities, had private or non-Medicaid public payers, and those treating elderly
patients. On the other hand, we found that TMH adoption was less likely among mental health
facilities treating more African Americans or patients with substance abuse disorders. State-level
factors associated with TMH adoption included: having special telehealth licensure for crossstate telehealth practices and having a high percentage of rural counties. Our findings suggest
that TMH adoption among mental health facilities may be discouraged by the legal/regulatory
burden on providers in seeking licenses for cross-state practice and by low IT capacity. In
addition, our findings suggest there may also be racial disparities in TMH access and missed
opportunities for utilizing TMH to treat substance abuse disorders.
TMH Use among Commercially Insured Adults with MHC
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Approximately 16 in 10,000 adults with MHC and 47 in 10,000 of those enrolled in
Medicare Advantage (MA) in underserved areas used TMH. Most TMH services were delivered
by psychiatrists. TMH has mostly been used for consultations and pharmacological management.
Psychotherapy delivered via TMH was rare relative to that delivered in-person. Patient
characteristics associated with TMH use included: younger age, having higher monthly out-ofpocket expenditures, past mental health specialist visits, and diagnosis of a severe MHC. TMH
use varied widely across states and was positively associated with high levels of shortages in
mental health providers and with high TMH capacity of mental health facilities in the state. Our
results suggest that current TMH use among adults with MHC was primarily driven by a need for
accessing mental health specialists. Expanding TMH capacities among mental health facilities
could help alleviate the unmet need for MH services.
Impact of TMH use on Healthcare Costs
We found that TMH use was associated with a greater likelihood of using MH services
and with significantly higher MH-related costs. Furthermore, using any TMH service was
associated with a greater increase in MH-related costs from baseline to follow-up as compared to
having only in-person MH service use. However, TMH use did not have any significant impact
on total third-party healthcare costs despite increased MH-related costs. Our findings suggest
that TMH use may help increase access to MH services without raising total healthcare costs.
5.2 Implications
This dissertation research revealed that facility-level IT capacity and state licensure
policies/requirements for cross-state telehealth practice played essential roles in shaping the
likelihood of TMH adoption among mental health facilities. Furthermore, the study findings
suggested a positive association between TMH adoption by mental health facilities and TMH use
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among adults with MHC. These findings have important implications for state policymakers. As
of 2017, medical boards in nine states had established processes to issue telehealth-specific
licenses to allow out-of-state providers to provide telehealth services,77 and twenty-two states
had adopted the Federation of State Medical Board’s Interstate Medical Licensure Compact to
allow an expedited process of applying for licenses in other states.77 Similar policy initiatives
that can reduce mental health providers’ legal/regulatory burden of adopting TMH are needed to
increase TMH capacity and thereafter encourage TMH use among adults with MHC.
Our study findings also have implications for state and federal funding agencies. As early
development of TMH requires capital funds and infrastructure development,148 funding agencies
need to be aware of the challenges faced by mental health facilities. Planning and securing
funding for facilities that are in the early stage of developing a TMH system is critical to
building TMH capacities.
The study findings also have implications for mental health facilities and mental health
providers. We found that TMH adoption was more likely among mental health facilities with
higher patient volumes and comprehensive MH treatments. It has been reported that telehealth
technology can improve physician efficiency by reducing waiting times and missed
appointment.136,149,150 Mental health facilities and providers aiming to increase their care capacity
may plan to implement TMH in their practice. However, for a TMH program to be successful
and beneficial to the operation, mental health facilities and providers need to coordinate the
volume and scheduling of TMH services with in-person services.151 Furthermore, mental health
facilities and providers need to keep up with proper training and guidelines to increase clinicians'
comfort and confidence in delivering various MH services via TMH.114,118
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Currently, the majority of TMH services were delivered by psychiatrists. Additional
research is needed to explore how to increase TMH use by allied mental health providers such as
psychologists, social workers, counselors, and nurse practitioners, who play important roles in
providing in-person mental healthcare. Pharmacological management is an essential part of
mental healthcare. Given the increasingly important role that pharmacists are playing in
comprehensive medication management in collaborative care models, future research needs to
explore the feasibility, acceptability, and outcomes of pharmacist-delivered, TMH based
medication management.116
Our findings can inform TMH-related policymaking by payers and other stakeholders.
The current healthcare system is transforming patient-centered care to meet the "Triple Aim"
goals for improving patient experience, population health, and reducing the cost of care.61 TMH
offers a unique opportunity to achieve patient-centered care by integrating mental and physical
health in primary care settings.138 Our results that TMH use could increase access to MH services
without having a significant impact on total healthcare costs provide initial evidence of the value
of TMH for the decisions of TMH expansion.
Although the study was not able to illustrate the mechanism, the study findings indicated
that the costs of increased MH service use might be offset by potential cost-savings from
improved physical health. Future studies should examine the sources of this apparent “costoffset” and explore whether TMH use can lead to cost-savings over a longer period.
Furthermore, although TMH provides a viable mechanism of mental health integration, how to
incorporate TMH into existing in-person care to maximize access to care is still under
discussion. Several care models have been piloted, including direct service models, consultation
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models, and collaborative care models.138 Further research is needed to explore the best care
model of incorporating TMH into primary care.
5.3 Unique Contributions of this Study
This study filled a critical knowledge gap. To our knowledge, this is the first populationbased study that comprehensively examined TMH adoption and associated facility- and statelevel factors among mental health facilities in the US. Our study findings offer insight into
factors that may influence facility-level decisions to invest in TMH and suggest potential
strategies to increase adoption. This is also the first study to evaluate the impact of TMH use on
total third-party healthcare costs and MH-related costs among commercially insured adults with
MHC. The findings provide initial real-world evidence for the value of TMH services in
facilitating the delivery of MH services, which can inform healthcare payers’ decision regarding
TMH expansion. By examining how TMH is used in delivering various MH services and which
providers and patients use TMH most, our findings suggest directions for healthcare insurers and
policymakers to better incorporate TMH in the current MH delivery system.
5.4 Strengths and Limitations
The strengths of this study include the use of diverse data sources to investigate the
current state of TMH delivery, the use of population-based, linked nation-wide data that permits
the examination of various multi-level factors, the use of robust statistical techniques to adjust
for observed and unobserved selection bias, the use of a pre-post nonequivalent controlled group
design to assess the comparability of costs across study groups, and the use of standardized
prices of medical services and prescription medications to allow comparison of MH care costs
across different geographical areas.
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Some limitations should also be noted. First, we estimated TMH adoption based on the
reported telemedicine use among mental health facilities. Due to the lack of data on how
telemedicine was used, we may have overestimated TMH adoption and use among mental health
facilities in the US. Second, we only have the data to measure environmental factors and market
characteristics at the state level and were therefore unable to capture within-state variation in
these factors. Third, the results may be affected by unmeasured factors that were not captured in
claims data, such as disease severity, race/ethnicity, education levels, and patient and provider
preferences. Furthermore, subgroup analyses of individual MHC’s or specific MH services were
not possible due to small sample sizes of TMH users in these groups. Finally, the study findings
of aim 2 and aim 3 may not be generalizable to adults with MHC who are insured by other
commercial insurances.
5.5 Conclusion
Although TMH appears to offer a promising tool for facilities to expand access to care
and serve high-need patients, only one in four mental health facilities had adopted TMH in 2016.
TMH adoption might be hindered by low facility-level information technology capacity and state
licensure requirements for cross-state telehealth practice. TMH use among adults with MHC was
low in this study of a commercially insured population. Current TMH use among adults with
MHC was driven mainly by a greater need to access mental health specialists. Collaborative
efforts by policymakers, payers, and providers, particularly those who could expand TMH
capacity in healthcare settings, are needed to increase the availability of TMH in mental health
care delivery, and thereby increase access to mental healthcare services for adults with MHC.
TMH can increase access to MH care without increasing total healthcare costs among adults with
MHC. Further research is needed to confirm our study findings; specifically, studies are needed
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to examine how TMH use affects the costs of mental and physical care separately and to explore
whether TMH use can lead to cost-savings over a longer period among adults with different
MHC.
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7 Appendices
Appendix 7.1 Procedure codes and modifiers used to identify mental health visits.
90791
90792
90785
90832
90833
90834
90836
90837
90838
90839
90840
00104
9424
9426
9427
80100
80101
80102
80103
80152
80154
80156
80160
80164
80166
80173
80174
80178
80182
80201
82055
82075
82145
82205
82520
82742
83840
83925
90801
90802
90804
90805
90806
90807
90808
90809
90810
90811
90812
90813
90814
90815

90816
90817
90818
90819
90820
90821
90822
90823
90824
90825
90826
90827
90828
90829
90830
90835
90841
90842
90843
90844
90845
90846
90847
90848
90849
90853
90855
90857
90862
90865
90867
90868
90870
90871
90872
90875
90876
90880
90882
90885
90887
90889
90899
95881
95882
95883
96100
96110
96111
96115
96117
W1023

W1027
W1030
W1032
W1033
W1035
W1037
W1038
W1039
W1044
W1046
W1048
W1049
W1050
W1059
W1061
W1064
W1065
W1070
W1074
W1075
W9890
W9891
W9892
W9892
G0071
G0072
G0073
G0074
G0075
G0076
G0077
G0078
G0079
G0080
G0081
G0082
G0083
G0084
G0085
G0086
G0087
G0088
G0089
G0090
G0091
G0092
G0093
G0094
G0176
G0176
G0177
G0442

G0443
G0444
H0001
H0001, HN
H0001, HO
H0001, TS
H0002
H0003
H0004
H0004, HR
H0004, HF
H0004, HG
H0004, HQ
H0005
H0006
H0007
H0008
H0009
H0010
H0011
H0012
H0013
H0014
H0015
H0016
H0017
H0018
H0019
H0020
H0022
H0023
H0031
H0031, TS
H0031, HA
H0031, HO
H0031, TS
H0031, HN
H0031, HM
H0032
H0032, HK
H0032, TS
H0033
H0034
H0035
H0036
H0037
H0038
H0039
H0040
H0043
H0044
H0046

96

H0046, HE
H0047
H0048
H0049
H0050
H2000, HO
H2000, HP
H2000
H2010, HO
H2010, HP
H2010, HE
H2010, HQ
H2010, HM
H2010, HF
H2010
H2010, HN
H2011
H2012
H2012, HF
H2013
H2014
H2015, HE
H2015, HN
H2015, HQ
H2015
H2016
H2017
H2018
H2019, HO
H2019, HM
H2019, HN
H2019
H2019, HR
H2019, HQ
H2020
H2021
H2022
H2023
H2024
H2025
H2026
H2027
H2028
H2029
H2030
H2031
H2032
H2033
H2034
H2035
H2036
H500

H5010
H5020
H5025
H5030
H540
H550
M0064
S0201
S5100
S5101
S5102
S9475
S9480
S9485
S9976
T1006
T1007, U8
T1007, SA
T1007
T1007, TS
T1008
T1011
T1012
T1015
T1015, HE
T1015, HF
T1015
T1015, HE
T1015
T1017
T1017, HA
T1017, HB
T1017, HK
T1017, TL
T1023, HE
T1023, HF
T1025
T1026
T2010
T2011
T2016
T2019
T2034
Z0001
Z0002
Z0002
Z0003
9401
9402
9403
9408
9409

9411
9412
9413
9419
9421
9422
9423
9425
9429
9431
9432
9433
9434
9435
9436
9437
9438
9439
9441
9442
9443
9444
9445
9446
9449
9451
9452
9453
9454
9455
9459
9461
9462
9463
9464
9465
9466
9467
9468
9469
96101
96102
96118
96119
96103
96116
96120

Appendix 7.2 Chapter 4 supplemental table: Marginal effects estimated from multivariable
difference-in-differences (DID) analyses of total healthcare costs and mental health (MH)-related
costs among adults with mental health conditions (MHC), Optum Clinformatics ® DataMart,
2010-2017
Marginal effect

TMH use (yes vs. no)

Total costs
Mean (95%CI)
-253.9 (-1601.5 1093.7)

MH costs
Mean (95%CI)
461.3 (142.4, 780.2)**

Time (follow-up vs. baseline)

-197.1 (-307, -87.2)***

-269.9 (-294.3, -245.5)***

DID

554.3 (-1005.2, 2113.8)

369.6 (13.9, 725.4)*

Predisposing factors a
Age (years)

37.5 (31.5, 43.5)***

-11.0 (-12.5 -9.4)***

Sex (female vs. male)

-57.2 (-212.0, 97.6)

-181.9 (-219.4, -144.5)***

Enabling factors a
Medicare Advantage (yes vs. no)
HMO (yes vs. no)

1257.3 (995.3, 1519.3)***
-449.9 (-675.8 -224.1)***

366.5 (310.3, 422.7)***
115.7 (61.3, 170.1)***

Need factors a
Any Severe MHC (yes vs. no)
Any MH specialist visit (yes vs. no)
Number of physical chronic conditions b

2199.8 (2036.5, 2363.1)***
156.2 (0.6, 311.9)*

328.9 (293.8, 364.1)***
201.5 (167.9, 235.1)***

One
Two or more
None
Polypharmacy c (yes vs. no)

2492.4 (2279.5, 2705.3)***
5152.4 (4921.4, 5383.5)***

362.7 (309.7, 415.6)***
458 (406.5, 509.6)***

5447.5 (5285.3, 5609.8)***

321.6 (280.4, 362.9)***

***

Any tobacco/alcohol use disorder (yes vs. no) 3981.2 (3812.8, 4149.6)
Any drug use disorder (yes vs. no)
4798.9 (4440.0, 5157.8)***
Obesity (yes vs. no)
2108 (1900.4, 2315.7)***
Environmental factors
Poverty d

201.3 (170.5, 232.2)***
382.9 (336.5, 429.3)***
65.7 (5.6, 125.9)*

High (3rd & 4th quartile)
Low (1st & 2nd quartile)
Rurality d

81.7 (-76.9, 240.2)

73.0 (34.0, 112.0)***

High (3rd & 4th quartile)
Low (1st & 2nd quartile)
Mental health provider shortage d

-165.4 (-329.1, -1.6)*

6.1 (-36.5, 48.8)

High (3rd & 4th quartile)
Low (1st & 2nd quartile)
TMH capacity e

122.5 (-46.7, 291.6)

-21.0 (-63.4, 21.4)

High (3rd & 4th quartile)
Low (1st & 2nd quartile)
Year of TMH use
Lagging time, days

156.9 (-27.5, 341.2)

-28.3 (-75.9, 19.2)

-164.5 (-198.7 -130.4)***
-2.7 (-3.4, -2.0)***

-8.0 (-16.8, 0.8)
-2.1 (-2.2, -1.9)***
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Note: a all patient-level factors were measured in the six-month period before and after index date based on deidentified claims of Optum Clinformatics ® DataMart. The first TMH use date was used as index date for users
and a pseudo-index date was randomly selected from all mental health service dates among non-users.
b
chronic conditions examined included arthritis, asthma, coronary artery disease, cardiac arrhythmias, congestive
heart failure, chronic kidney disease, chronic obstructive pulmonary disease, dementia and related disorders,
diabetes, hypertension, hyperlipidemia, osteoporosis, stroke.
c
polypharmacy was defined as having five or more medications from different therapeutic classes in the 90 days
before index date.
d
poverty, rurality, and mental health provider shortage were measured as average percentages of counties under
qualified for each condition from 2010-2016 based on data from the 2016-2017 Area Health Resources File.
e
TMH capacity was measured as average percentages of mental health facilities with telemedicine from 20102016 based on data from the 2010-2016 National Mental Health Services Survey.
*
, p < 0.05; **, p < 0.01; ***, p < 0.001.
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